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Sequential Quantile Estimation Using Continuous Outcomes
with Applications in Dose Finding
Chih-Chi Hu
We consider dose finding studies where a binary outcome is obtained by dichotomizing
a continuous measurement. While the majority of existing dose finding designs work
with dichotomized data, two procedures that operate on continuous measurements
have been proposed. One is based on stochastic approximation and the other on least
square recursion. In both cases, estimating the variance of the continuous measure-
ment is an integral part of the design. In their originally proposed forms, variance
estimation is based on data from the most current cohort only. This raises the ques-
tion of whether performance of the two designs can be improved by incorporating
better variance estimators. To this end, we propose estimators that pool data across
cohorts. Asymptotic properties of both designs with the proposed estimators are de-
rived. Operating characteristics are also investigated via simulations in the context
of a real Phase I trial. Results show that performance of least square recursion based
procedure can be substantially improved through pooling data in variance estimation
while performance of stochastic approximation based procedure is only marginally
improved.
The second problem considered in this dissertation deals with the limitation shared
by both designs that complete follow-up of all current patients is required before new
patients can be enrolled. This may result in impractically long trial duration. We con-
sider situations where besides the final measurement that the outcome of the study is
defined on, each patient has an additional intermediate continuous measurement. By
extending least square recursion through incorporating intermediate measurements,
continual patient accrual is allowed. Simulation results show that under reasonable
patient accrual rate, the proposed procedure is comparable to the original in terms
of accuracy while shortening the trial duration considerably.
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Dose finding in early phase clinical trials is often formulated as a quantile estimation
problem. In a study where the primary goal is to evaluate safety of a new drug or
treatment, the objective is typically to identify the maximum tolerated dose (MTD),
defined as the dose associated with an acceptable level of toxicity rate [29]. When
assessment of efficacy is the primary concern, the outcome of interest is therapeutic
response (or “success”). In this case, the dose finding objective is to identify the
minimum effective dose (MED), defined as the dose associated with a given level of
response rate [10].
Designs proposed to address this quantile estimation problem predominantly uti-
lize binary data; that is, the outcome they operate on is the presence or absence of
the event of interest. Among such designs are the continual reassessment method
(CRM, [21]), escalation with overdose control (EWOC, [2]), biased coin design [12],
and logit-MLE [31, 32]. Sometimes, however, the binary outcome is obtained by
dichotomizing a continuous measurement. Consider the following two examples.
Several statins have been found to be neuroprotective in rodent acute stroke mod-
els in a dose-dependent fashion [13]. The Neuroprotection with Statin Therapy for
Acute Recovery Trial (NeuSTART) [13] was a phase 1B dose finding trial of short-
1
term high-dose lovastatin in acute ischemic stroke patients. Five escalating doses
of lovastatin (1, 3, 6, 8, 10 mg/kg/day) were chosen to evaluate safety and deter-
mine an optimal dose. Each of the 33 patients was given one of the escalating doses
for 3 days within 24 hours of symptom onset. After the initial 3 days, all patients
received standard dose (20mg) of lovastatin daily for 27 days. One of the primary
safety outcomes was major hepatic toxicity defined by clinical and laboratory criteria.
In particular, liver toxicity based on laboratory evidence was defined as elevation in
ALT level greater than three times the upper limit of normal (ULN). Toxicity was
evaluated up to 30 days after treatment initiation. When any of the safety outcome
occurred, the patient was considered to experience dose-limiting toxicity (DLT). The
objective of the trial was to determine the MTD of lovastatin, defined as the dose
that causes 10% of DLT rate.
The second example is an ongoing trial aimed to determine the MED of a problem-
solving therapy (PST) in patients with heart failure. PST is a cognitive-behavioral
therapy that helps patients solve their behavioral difficulties systematically and be-
come more physically active. The investigators hypothesize that PST will also im-
prove quality of life (QoL) in heart failure patients through increased physical activity,
increased exercise capacity and reduced depression. Five test doses of PST (2, 4, 6,
8 or 12 sessions) administered over an 8 week period are considered in the trial. A
planned 48 participants will be enrolled in cohorts of size three and the starting dose
is level 3 (6 sessions). Quality of life will be assessed at baseline, 4, 8 and 12 weeks.
The objective of the trial is to identify the number of PST sessions that yields a 66%
of response, defined as 10-point improvement in QoL between baseline and 8 weeks.
In both examples, the original measurements are continuous and based on which
binary outcomes are defined by dichomization. In situations like these, sequential
designs that operate on the dichotomized data could be sensitive to the dichotomiza-
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Figure 1.1: Liver function outcomes in the NeuSTART. Each “o” represents an ob-
servation and the dashed line the toxicity threshold of 3 times the ULN.
tion threshold and measurement error. This is illustrated by Figure 1.1 which displays
the maximum ALT level of the 33 patients from NeuSTART. As can be seen, two
DLTs occurred at dose level three. As these two measurements just exceeded the
threshold, a slight drop in them could have resulted in a different dose assignment,
which was carried out sequentially by a variant of the CRM. Another reason against
using dichotomized data is that information may be lost by disregarding the contin-
uous measurements. Motivated by these concerns, Cheung and Elkind [9] proposed
a novel variant of the Robbins-Monro stochastic approximation that utilizes continu-
ous outcomes for sequential quantile estimation. The Robbins-Monro procedure was
originally developed to estimate the root of an unknown regression function and is
well-suited for quantile estimation problems. However, when applied in a dose find-
ing setting, it is not efficient unless the outcomes are continuous [30]. Moreover, it
implicitly assumes a continuum of doses is available while in practice the test doses
are usually confined to a discrete set. As a result, the Robbins-Monro procedure is
rarely used in dose finding applications. The novel procedure, called stochastic ap-
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proximation with virtual observations (SAVOR), draws on the strength of stochastic
approximation by transforming the dose finding problem into root-finding for con-
tinuous variables. At the same time, it introduces a novel concept named virtual
observation to overcome the barrier presented by discrete doses.
In a related line of work, Hu and Cheung [14] proposed a design that also utilizes
continuous outcomes based on least square recursion (LSR). While the least squares
recursion was proposed with the assumption of availability of continuous doses, the
idea of virtual observation can be easily incorporated to accommodate discrete doses
(see Chapter 3). To the best of our knowledge, SAVOR and LSR are the only designs
that tackle sequential quantile estimation problem using continuous outcomes in the
dose finding literature. With both designs, estimation of mean and variance of the
continuous measurement is an integral part of the design. Estimation of the variance,
in particular, plays an important role and can have an sizable impact on the efficiency
of the design [14]. In this dissertation, we propose extensions of both SAVOR and
LSR through improved variance estimation in the hope of achieving greater efficiency.
So far, the designs mentioned require complete follow-up of all current patients
before new patients can be entered into the study. For studies with long observation
time this limitation may result in prohibitively long duration. As a case in point, in
the PST study, if we have to wait for 8 weeks between cohorts, it will take about
30 months to finish enrolling the planned 16 cohorts. Also, from an ethical point
of view, eligible patients may have to be turned away if currently enrolled patients
have not reached complete follow-up. With these considerations in mind, the time-to-
event continual reassessment method (TITE-CRM, [8]), a variant of the CRM that
allows patients to be entered in a staggered fashion is the proposed design for the
PST study. With TITE-CRM, the 4-week QoL measurement can be used to aid
dose assignment and thereby shortening the inter-cohort time from 8 to 4 weeks.
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However, besides the possible loss of efficiency associated with dichotomized data,
there is another limitation that comes with TITE-CRM. Namely, the design assumes
an observed response at any time during follow-up as a complete observation. Under
the current context, this means that if a response, i.e. ≥ 10-point improvement in
QoL, is observed at 4 weeks, then it is implicitly assumed that the improvement
will sustain and a response will also be observed at 8 weeks. This is an unrealistic
assumption to make as the change in QoL may fluctuate over time. Despite not being
ideal, TITE-CRM was chosen for lack of a better alternative. To fill the gap in the
literature, we propose an extension of the LSR to incorporate intermediate continuous
outcomes.
This dissertation is structured as follows. In Chapter 2, we shall formally define
the dose finding objective and briefly review a few of the designs that utilize binary
data. Designs using continuous outcomes are reviewed in Chapter 3. In Chapter 4,
SAVOR and LSR are extended to incorporate improved variance estimators. Chapter
5 presents the extension of LSR that accommodates intermediate outcomes.
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Chapter 2
Dose Finding Designs Using
Binary Outcomes
2.1 Introduction
This chapter reviews some dose finding designs that operate on binary data. As
the development of most of these designs was motivated by safety studies, we will
present them in this context. Their applications to efficacy studies can be derived
analogously. Before presenting the designs, a formal definition of the MTD is given.
The MED can be defined in a similar fashion.
2.2 Maximum Tolerated Dose (MTD) as Percentile
Consider a trial in which the patient population is homogeneous. Let T be the binary
indicator of dose-limiting toxicity (DLT) for a patient, then the probability of toxicity
at dose x is π(x) = P (T = 1|x). For now, assume that π(x) is strictly increasing in
x. Given a level of toxicity of interest p, the dose finding objective is to identify the
6
MTD, defined as the dose θ such that
π(θ) = p. (2.1)
When the doses are confined to a discrete set of K levels labelled as 1, . . . , K, the
MTD can be defined as the dose that has toxicity probability closest to p:
ν1 = arg min
k
|π(k)− p|. (2.2)
This formulation of viewing MTD as a percentile on the dose-toxicity curve is
in line with bioassay and statistically appealing in that the MTD is a well-defined
quantity (with suitable conditions on π) to be estimated [6]. Also, the target toxicity
probability p can be decided on a trial by trial basis to suit the specific application.
For the definition of MED, replace dose-toxicity curve with dose-response curve.
That is, let π(x) = P (R = 1|x) where R is the binary indicator of response. Then θ
in (2.1) and ν1 in (2.2) become the MED.
2.3 3+3 Algorithm
The 3+3 algorithm is the first algorithm-based design to be widely used in clinical
practice and has remained the prevailing method for conducting phase I cancer clinical
trial [17]. Generally, an algorithm-based design requires no modelling on the dose-
toxicity relationship beyond the assumption that toxicity increases with dose. It
prescribes a set of escalation (and/or de-escalation) rules for any given dose without
taking outcomes at other doses into account.
The 3+3 algorithm starts at a safe dose (e.g., one tenth of the mouse equivalent
LD10) and escalates according to the following rules:
1. Evaluate three patients at current dose
(a) If zero out of three has DLT, then escalate to the next higher dose and go
to step 1;
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(b) If one of three has DLT, then go to step 2;
(c) If more than one of three have DLT, then go to step 3.
2. Evaluate an additional three patients at current dose:
(a) If one of six has DLT, then escalate to next higher dose and go to step 1;
(b) If more than one of six have DLT then go to step 3.
3. Discontinue dose escalation.
If the trial is stopped then the MTD is estimated by the dose immediately below
the terminating dose. If there are only three patients evaluated at that dose level,
some protocols add another three patients. In which case, the estimated MTD is the
highest level with at most one DLT out of 6 patients.
Similar designs with different cohort sizes and expansion rules have been proposed.
The traditional 3+3 algorithm can be viewed as a special case of a class of A+B
designs in which an additional cohort of B patients is added if the number of DLT
exceeds some threshold in the first cohort of A patients. The key statistical properties
of A+B designs were investigated in Lin and Shih [19].
The main advantage of the 3+3 algorithm is its simplicity. However, it has been
criticized for involving an excessive number of escalation steps [17]. This is partic-
ularly undesirable in trials with therapeutic intent as a large proportion of patients
would be treated at low and potentially subtherapeutic doses while few would actually
receive doses at or near the recommended MTD. Another criticism is that specifica-
tion of a target probability of toxicity is not allowed. Thus, the notion of viewing
MTD as a percentile on the dose-toxicity curve does not apply. In fact, there is no
intrinsic property that yields a good estimate of MTD and the distribution of the
estimated MTD depends arbitrarily on the number and actual percentiles of the dose
levels examined [5].
Despite its drawbacks, the 3+3 algorithm is still widely used in practice. This is
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due mainly to its algorithm-based simplicity in logistics for the clinical investigators
to carry out [19].
2.4 The Continual Reassessment Method
The continual reassessment method (CRM), introduced by O’Quigley, Pepe and
Fisher [21] was the first Bayesian model-based method proposed for adoption in phase
I trial designs. Briefly, a model-based design makes dose decisions based on an as-
sumed dose-toxicity curve and utilizes all accrued data to repeatedly update the
curve. The general idea behind the CRM is that a dose-toxicity curve would be fit-
ted to the data and that each patient would be assigned the dose most likely to be
associated with the target toxicity level. The process starts with an assumed a priori
dose-toxicity curve. The estimated dose-toxicity curve is refit after each patient’s tox-
icity outcome was observed. At every stage, the next patient is assigned the current
model-based MTD estimate.
2.4.1 The Basic Approach
We consider first a fully sequential version, in which patients are enrolled one at a
time. Assuming there are K test doses with numerical labels d1, . . . , dK , let Tn be
the indicator of toxicity for the nth patient who receives dose xn ∈ {d1, . . . , dK}. It
is assumed that Tn is a Bernoulli variable with toxicity probability π(xn) and that
π(x) is monotone increasing in x. The goal is to estimate ν1 as defined in (2.2). To
achieve this, the CRM assumes a working dose-toxicity model for π(x), denoted by
F (x, a). It should be noted that the CRM does not require F to be the correct model
for π. Among the conditions F needs to satisfy (see [5]), F (x, a) should be monotone
increasing in x for all a and monotone in a in the same direction for all x. Also, F
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should be flexible enough so that for any given p ∈ (0, 1) and given x, there exists a
such that F (x, a) = p. The two most commonly choices for F are the empiric function
F (x, a) = xexp(a), 0 < x < 1, (2.3)
and a one-parameter logistic function
F (x, a) =
exp (a0 + exp(a)x)
1 + exp(a0 + exp(a)x)
,−∞ < x <∞,
where the intercept a0 is a fixed constant.
The original CRM uses a Bayesian approach in which a is assumed to follow a prior
distribution H(a). The trials starts by treating the first patients at the prior MTD,
the dose initially believed to have toxicity probability equal or closest to p. Then for
n > 1, the dose assigned to the nth patient is the model-based MTD estimate:
xn = arg min
dk











Tj [1− F (xj, a)]1−Tj .
The process is continued until a prespecified number of patients N is reached. The
final MTD estimate is xN+1.
One important aspect of CRM is that the dose labels d1, . . . , dK are not the doses
administered, but are numerical representation of the risks of toxicity defined on some
conceptual scale [5]. More precisely, let pk be the initial guess of probability of toxicity
associated with dose k and â0 the prior mean of a, then dk is obtained by solving
pk = F (dk, â0). Thus, specification of the initial guesses p1, . . . , pK is an essential part
10
Table 2.1: Starting dose escalation plan in the NeuSTART
Cohort Cohort Lovastatin dose
size 0–72 hours days 3–30
(mg/kg/day) (mg/day)
1 3 1 20
2 3 3 20
3 3 6 20
4 3 6 20
5 3 8 20
6 3 8 20
7 3 8 20
8 3 10 20
9 3 10 20
10 3 10 20
11 3 10 20
of a CRM design. A systematic approach to selecting the initial guesses was proposed
by Lee and Cheung [18].
Instead of enrolling patients one at a time, cohort accrual can be easily accommo-
dated in the CRM by assigning the same dose to a cohort of m > 1 patients. In this
case, the MTD estimate (2.4) is updated between cohorts.
2.4.2 Some Variations of CRM
In response to the concern that the use of prior information may be arbitrary and
have lingering impact on dose selection, O’Quigley and Shen [22] proposed a version of
CRM that is based on likelihood framework. Under this framework, the model-based
MTD estimate for the nth patient is
xn = arg min
dk
|F (dk, ãn−1)− θ|
where ãn−1 = arg maxa Ln−1(a) is the maximum likelihood estimate of a. In order to
base inference on the likelihood, it is necessary to have a nonmonotone likelihood. In
other words, for ãn−1 to exist, heterogeneity among the toxicity outcomes is needed.
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Figure 2.1: Patient flow of NeuSTART. Each point represents a patient, with “o”
indicating no toxicity and “x” indicating toxicity.
One way to ensure this is to adopt a two-stage design described as follows. Let {xn,0}
be a prespecified nondecreasing dose sequence such that xn−1,0 ≤ xn,0. The dose
assignments follow this initial sequence until the first observed toxicity. After which
the trial will switch to the CRM. As an example, dose escalation for the NeuSTART
was done in two stages. The initial escalation plan is shown in Table 2.1 and the trial
outcomes in Figure 2.1. After the eighth patient experienced DLT, the trial turned
to the CRM. The trial stopped when the planned 33 patients were enrolled and the
CRM recommended dose level 4 as the final MTD estimate.
2.4.3 The Time-to-Event CRM
Both 3+3 algorithm and the CRM require all currently enrolled patients be completely
followed before the next patient or cohort can be enrolled. An extension of CRM,
called time-to-event continual reassessment method (TITE-CRM, [8]) was proposed
by Cheung and Chappell to address this limitation by allowing patients to be enrolled
in a staggered fashion. Specifically, TITE-CRM allows for incomplete observations
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Ti,n+1 [1− wi,n+1F (xi, a)]1−Ti,n+1 ,
where Ti,n+1 is the indicator of DLT and wi,n+1 the weight for patient i prior to
the entry of patient n + 1. The weight wi,n+1 reflects the amount of information
contributed by patient i and therefore should increase with follow-up time. A simple
weight function is the linear weight. Let D be the observation window, that is, the





if a patient is in follow-up and has not experienced a DLT at time t
1 if a patient has experienced DLT or has been followed for D.
Having defined the weighted likelihood, the estimation of a and the model-based MTD






xn+1 = arg min
dk
|F (dk, âwn )− p|.
Note that TITE-CRM reduces to regular CRM if new patients are enrolled only after
follow-ups are complete for current patients.
Since TITE-CRM does not require suspension of patient accrual in order to wait
for toxicity outcomes on previous patients, it can greatly reduce the trial duration
compared to regular CRM. However, in situations of fast accrual and late-onset tox-
icities, TITE-CRM is more likely to assign new patients to doses considered safe at
the time but later found otherwise [3]. To reduce the risk of exposing patients to




The 3+3 algorithm and the CRM are representatives of algorithm- and model-based
designs, respectively. A third class of design is based on stochastic approximation.
Robbins and Monro [25] introduced the subject of stochastic approximation for finding
the unique root of a regression equation. The problem they addressed can be stated
as follows:
Let Y = Y (x) denote a random variable with expectation Q(x) at level x. The
function Q(x) is unknown to the experimenter but Y at different values of x can be
observed. The objective is to sequentially approach the root x = x∗ of the equation
Q(x) = α (2.5)
for given α. The Robbins-Monro procedure for finding x∗ starts with an prespecified
X1 and defines
Xn+1 = Xn −
1
nb
(Yn − α), (2.6)
for some b > 0.
Under Conditions A.1, A.2 and A.3 (a) listed in Appendix A, the sequence Xn
generated by (2.6) converges to x∗ with probability one. If in addition, b < 2Q′(x∗)










2.5.2 Stochastic Approximation in Dose Finding Setting
The possibility of adapting stochastic approximation to dose finding setting was first
discussed by Anbar [5]. If Y is the binary indicator of DLT, x the dose level, Q(x) =
π(x) = P (Y = 1|x), and α = p, then solving for (2.5) is equivalent to estimating the
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MTD under definition (2.1). In a trial with N patients, the final estimated MTD can
be taken to be the last design point, XN+1. Despite its seemingly suitability, there are
some practical considerations that prevent applications of stochastic approximation
in dose finding settings. First, the choice of b in (2.6) is of the utmost importance.
The asymptotic normality result depends on b being less than an unknown quantity,
namely b < 2Q′(x∗). Moreover, considering efficiency in terms of asymptotic variance,
the optimal choice would be setting b equal to Q′(x∗). The second issue is that the
procedure entails the availability of a continuum of doses which is usually not feasible
in practice [9].
The first issue has been addressed by replacing b by a sequence bn that is strongly
consistent for Q′(x∗). Anbar [1] suggested an adaptive procedure that sets bn to be











where X̄n = n
−1∑n
i=1Xi, Ȳn = n
−1∑n
i=1 Yi and c1, c2 are positive constants such
that c1 < b < c2. The adaptive procedure is theoretically ideal in that bn → Q′(x∗)
a.s. and the design sequence {Xn} achieves minimal asymptotic variance [16]. In
applications with small samples, however, estimation of Q′(x∗) could cause numerical
instability [6].
One solution to the second issue is to use a discretized version of the stochastic
approximation. Suppose there are K doses labelled as {1, . . . , K}, then a discretized














1 if x < 0.5,
[x+ 0.5] if 0.5 ≤ x < K + 0.5,
K if x ≥ K + 0.5.
(2.8)
While this may seem to be a straightforward solution to accommodate discrete doses,
rounding creates a problem called discrete barrier, meaning that the output from
(2.7) may be confined at a incorrect dose indefinitely. Illustrations of discrete barrier
can be found in Cheung [6] and Shen and O’Quigley [28].
The performances of discretized version of both non-adaptive and adaptive Robbins-
Monro procedure were compared to a fully sequential CRM in a simulation study
carried out by O’Quilgley and Chevret [20]. It was found that in general, CRM
performed the best in terms of correctly identifying the MTD.
2.6 Logit-MLE
Wu [31] took a different approach to solve for (2.5). His method is to first specify
a parametric model for Q(x) then repeatedly estimate x∗ by the maximum likeli-
hood method based on currently accrued data. The design points are set to be the
latest estimates of x∗. This method, which was first introduced under the context
of binary data and later extended to include data from exponential family, is called
maximum likelihood recursion. In particular, when the outcome Yi is binary and
Q(x) = E(Yi|Xi = x) is assumed to take the form logit(Q(x)) = logit(α) + b̃(x− α)








1− α + αeb̃(Xi−x̂∗n)
)
= 0, (2.9)




Ying and Wu [33] showed, by first establishing an asymptotic equivalence to
an adaptive Robbins-Monro procedure that the design sequence {Xn} from (2.9)










Logit-MLE shares similar limitations as stochastic approximation in that it as-
sumes a continuum of doses and b̃ needs to be carefully chosen. In a simulation
study of small to moderate sample sizes with binary outcomes and continuous doses,
Wu [31] compared logit-MLE, the non-adaptive Robbins-Monro procedure with sev-
eral choices of b and the adaptive Robbin-Monro procedure with different truncation
bounds. It was concluded that logit-MLE is the superior of the three methods in
terms of mean squared error.
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Chapter 3
Dose Finding Designs Using
Continuous Outcomes
3.1 Introduction
In this chapter, we review two dose finding designs that utilize continuous outcomes.
The first is a variant of stochastic approximation; the second is based on least square
recursion, a versatile framework for sequential percentile estimation. As is the case
in chapter 2, the designs are presented in the context of safety trials.
3.2 Problem Formulation
Consider a trial in which patients are enrolled in successive cohorts of size m. Within
the ith cohort, let Xi be the dose given and Yij the observable continuous outcome of
the jth patient. A toxicity is said to occur if Yij is greater than a prespecified threshold
t0, that is, a binary toxicity outcome is defined by dichotomizing Yij. Throughout
the chapter, we assume the following semi-parametric model for Yij:
Yij = M(Xi) + σ(Xi)εij, i = 1, . . . , n, j = 1, . . . ,m, (3.1)
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where εij’s are independent and have a common distribution G with mean 0 and vari-
ance 1. Notice that the model assumes a homogeneous patient population. Assuming
for now that Xi is continuous, the objective of the trial is to estimate dose θ that
satisfies (2.1) for some prespecified p, where π(x) = P (Yij > t0|Xi = x). Given model







With this expression, the target dose θ is the root of
f(x) ≡M(x) + cp σ(x) = t0, (3.3)
where cp denotes the upper pth percentile of G. In words, the dose finding objective
(2.1) is now transformed into a root-finding problem for a continuous variable.
When the doses are discrete, that is, Xi ∈ {1, . . . , K}, the working objective can
be defined as the identification of ν1 = arg mink |π(k)− p|. Under the current setup,
an alternative objective is to identify
ν2 = arg min
k
|f(k)− t0|. (3.4)
The two objectives ν1 and ν2 represent the closest doses to θ on different scales.
To ensure the existence and uniqueness of ν1 and ν2, we require that both π(x) and
f(x) are weakly monotone in x:
Condition 3.1. For all k′ < ν1 − 1 and k > ν1 + 1,
1. π(k′) < π(ν1 − 1) < π(ν1) < π(ν1 + 1) < π(k)
2. f(k′) < f(ν1 − 1) < f(ν1) < f(ν1 + 1) < f(k)
While ν1 and ν2 are not necessarily identical, ν2 is either equal to ν1 or one of ν1’s
immediate neighbours, that is, ν2 ∈ {ν1 − 1, ν1, ν1 + 1} [9]. In particular, define ck
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such that G(ck) = 1−π(k) and let Bk = 2σ(k)|ck− cp| for k = 1, . . . , K, then ν1 = ν2
if and only if Bν1 = mink Bk. Relationship between ν1 and ν2 is explored in details in
Cheung and Elkind [9]. In accordance with convention, we will focus on estimation
of ν1.
3.3 Stochastic Approximation with Virtual Obser-
vations
Having re-formulated the dose finding problem, stochastic approximation can be ap-
plied to solve (3.3). For now, assume a continuum of doses is available. Define








where Ȳn = m
−1∑m
j=1 Ynj and S
2
n = (m − 1)−1
∑m
j=1(Ynj − Ȳn)2. Then E(Un|Xn) =
f(Xn) and Un’s can be used to generate a Robbins-Monro recursion:
Xn+1 = Xn −
1
nb
(Un − t0) for some b > 0. (3.6)
In particular, when G is standard normal,
Un = Ȳn + zp
√
λmSn, (3.7)





with Γ(·) being the gamma function.
Assume the following conditions are satisfied:
Condition 3.2. f(θ) = t0 and (x− θ)(f(x)− t0) > 0 for all x 6= θ.
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Condition 3.3. For all x and some positive constant D, |f(x)− t0| ≤ D|x− θ|. And
for every c1, c2 such that 0 < d1 < d2 <∞,
inf
d1≤|x−θ|≤d2
|f(x)− t0| > 0.
Condition 3.4. f(x) = t0 + α(x − θ) + δ(x, θ) where δ(x, θ) = o(|x − θ|) as x → θ
and α > 0.











To examine the advantage of using continuous outcomes as opposed to dichotomized
outcomes under the current setting, Cheung [6] compared recursion (3.6) assuming
normal noises to logit-MLE in terms of optimal asymptotic efficiency. The former was
found to be substantially more efficient when cohort sizes are larger than 2, especially
when p is extreme. In particular, when m = 3, the relative efficiency has a minimum
of 1.238 when p = 0.12 or 0.88 [6].
As mentioned in the previous chapter, one of the reasons that has impeded the
application of stochastic approximation in practice is that doses are usually confined
to a discrete set. To overcome this hurdle, Cheung and Elkind [9] introduced the
novel notion of virtual observation. Specifically, the virtual observation of the nth
cohort is
Vn = Un + β(X
∗
n −Xn),
where β > 0 and X∗n is called the assigned dose of cohort n that takes values on
a continuous conceptual scale, and Xn = C(X
∗
n) is the actual dose given with C
defined in (2.8). Setting X∗1 = X1 ∈ {1, . . . , K}, then stochastic approximation based
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(Vn − t0) . (3.10)
Instead of solving for θ, the solution to (3.3), recursion (3.10) solves for θβ, the
solution to
h(x) ≡ E(Vn|X∗n = x) = t0. (3.11)
Using previously defined notations, h(x) = f(C(x)) + β(x − C(x)). The existence
and uniqueness of the root to (3.11) depend on the choice of β. Cheung and Elkind
showed that
1. If Bν1 = mink Bk and Bν1 < β < mink 6=ν1 Bk then h(θβ) = t0 for some unique θβ
with C(θβ) = ν1 and Xn = ν1 eventually with probability one. If in addition,















Xn), then the asymptotic variance in (3.12) is
σ2(ν1)
1 +mz2p(λm − 1)
mb(2β − b)
.
2. If 0 < β < mink Bk then the root of h(x) = t0 does not exist. In this case, if
(a) π(ν1) < p then h(ν1 + 0.5−) < t0, h(ν1 + 0.5) > t0 and P (Xn ∈ (ν1, ν1 +
1) eventually) = 1.
(b) π(ν1) > p then h(ν1 − 0.5−) < t0, h(ν1 − 0.5) > t0 and P (Xn ∈ (ν1, ν1 −
1) eventually) = 1.
A point worth emphasizing is that by the construction of virtual observations, the
objective function h(·) has a known local slope β at the root θβ. This feature makes
stochastic approximation stable and reliable in small-sample settings [9].
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In view of minimizing asymptotic variance in (3.12), it would be ideal to set b = β
and β as large as consistency condition would allow. However, the condition depends
on Bk’s, which are unknown quantities. Guidelines on calibration of β were provided
by Cheung and Elkind [9] under scenarios where the following two conditions are met:
Condition 3.5. π(ν1) = π(ν2) = p, π(k) ≤ pL < p < pU ≤ π(k′) for k < ν1 < k′ and
some prespecified limits pL, pU .
Condition 3.6. σ(k) depends on dose k only via M(k) as follows: s(σ(k)) = s(σ(θ))+
φ(M(k) −M(θ)) for some φ ≥ 0 and some smooth function s(σ) with s(σ) ≥ 0 and
s′(σ) > 0
Under Condition 3.5, there is an unambiguous target θ = ν1 = ν2 = θβ. Together









, cp − cU
}
, (3.13)
where cL = G
−1(1 − pL) and cU = G−1(1 − pU). The authors suggested that the
unknown quantity σ(θ) be estimated by σ0, the estimated standard deviation of the
safety measurement in a comparable untreated population.
In a redesign of NeuSTART, Cheung and Elkind compared SAVOR to CRM via
simulations and found the former superior in terms of probability of selecting the
MTD. They also demonstrated that SAVOR is robust to misspecification of distribu-
tion in model (3.1) and the superiority over CRM maintains under several different
distributions.
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3.4 Least Square Recursion with Virtual Observa-
tions
Another framework of designs for sequential estimation of θ using continuous data
was proposed by Hu and Cheung [14]. For any n, let Uin be equal to Ui as defined in







t0 + b(Xi − θ̂n)
]}
= 0, for some b > 0. (3.14)
Equation (3.14) comes from assuming the working model f(x) = t0 + b(x − θ) then
estimating θ by method of least squares. Setting the design point for the next cohort
to
Xn+1 = θ̂n
then the least square recursion (LSR) based on Uin is





(Uin − t0) . (3.15)
A direct application of Lemma 1 in Lai and Robbins [15] shows that recursions
(3.15) and (3.6) are equivalent. Thus, standard asymptotic results from stochastic
approximation can be applied if appropriate conditions are satisfied.
Similar to traditional stochastic approximation, recursion (3.15) assumes availabil-
ity of continuum of doses. The idea of virtual observation can easily be incorporated
into least square recursion to accommodate discrete doses. Let
Vin = Uin + β(X
∗
i −Xi), i = 1, . . . , n,








(Vin − t0) , (3.16)
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i . Results from SAVOR apply since (3.16) is
equivalent to (3.10).
A few comments on recursions (3.10) and (3.16) are in order. First, since the
update is done on the continuous X∗ without rounding, discrete barrier problem
is circumvented. Second, both the use of continuous outcome and the distribution
assumption in model (3.1) contribute to the efficiency gain over procedure using di-
chotomized data 1{Yij > t0}. In contrast, no distributional assumption is required in
logit-MLE and CRM. While robustness against misspecification in G has been estab-
lished under Conditions 3.5 and 3.6 in Cheung and Elkind [9], further investigation
needs to be done for more general scenarios. Third, due to the need to estimate
variance function σ(·), only group accrual are permitted in SAVOR and LSRVO as
opposed to the possibility of individual enrolment in CRM and logit-MLE. Lastly,
while (3.16) and (3.10) are equivalent under the current formulation, it is not hard
to see that as a general framework, (3.16) is the more versatile of the two. This is
mainly because (3.16) works with triangle arrays and therefore has the potential to
accommodate more complicated situations. This last observation will become clear
in subsequent chapters.
3.5 Efficiency and Variance Assumptions
3.5.1 Variance Assumptions
Under the current setting, a correct specification of the standard deviation function
σ(·) in model (3.1) is important. So far, we have left σ(·) unspecified and estimated
it nonparametrically. While putting additional assumption on σ(·) may improve
efficiency, such endeavour should be proceeded with caution. With sequential designs,
any assumption on σ(·) will be directly involved in the generation of design points
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and hence sensitivity analysis may not be performed after data are collected. In this
section, we look into how much information can be retrieved by placing additional
parametric assumptions in model (3.1) while keeping the mean M(x) unspecified.
Since the goal is to investigate the impact of variance assumption on efficiency, doses
are assumed to be continuous and the objective is to identify θ, the root to (3.3).
Both stochastic approximation (3.6) and least square recursion (3.15) are considered.
It is also assumed that G follows standard normal; Conditions 3.2, 3.3, and 3.4 are
met and that b < 2f ′(θ).
We consider three sets of assumptions on σ(·):
Case 1 (known variance): Assume σ(x) is completely known. It is natural to define
Un = Ȳn + zpσ(Xn) for stochastic approximation , and Uin = Ȳi + zpσ(Xi) for least
square recursion.
Case 2 (heteroscedasticity): σ(x) is unknown and unspecified. This is the case con-
sidered in Sections 3.3 and 3.4. We let Un = Ȳn + zp
√
λmSn and Uin = Ȳi + zp
√
λmSi.
Case 3 (homoscedasticity): Assume σ(x) ≡ σ, where σ is unknown. In this case, a


















We note that homoscedasticity may not be a viable assumption in many practical
situations, and it is arguably the strongest parametric assumption one can impose on
σ(x) besides complete knowledge assumed under case 1. The consideration of case 3
is intended to serve as a reference for case 2, so as to shed light on how much efficiency
one may lose due to nonparametric estimation of σ(x).
Table 3.1 summarizes the procedures being considered by recursion and variance
assumption. The equivalence of LSR-c2 and SA-c2 and their asymptotic properties
have been discussed. Under case 1, the equivalence between stochastic approximation
and least square recursion also holds and standard asymptotic results can be applied
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Table 3.1: Summary of procedures
Least Square Recursion Stochastic Approximation
Assumption on σ(x) Xn+1 = X̄n − 1nb
∑n
i=1 (Uin − t0) Xn+1 = Xn −
1
nb (Un − t0)
Case 1 (known variance)
LSR-c1 SA-c1
Uin = Ȳi + zpσ(Xi) Un = Ȳn + zpσ(Xn)
Case 2 (heteroscedasticity)
LSR-c2 SA-c2
Uin = Ȳi + zp
√






























The equivalence of stochastic approximation and least square recursion breaks down
under case 3. Moreover, standard asymptotic results can be applied to neither SA-c3
nor LSR-c3 because the summands are correlated in a complex way via Ui and Uin.
To establish asymptotic property of LSR-c3 under homoscedasticity, Hu and Cheung
[14] first showed LSR-c3 can be seen as a Robbins-Monro procedure with some small
bias that does not affect the asymptotic properties.
Lemma 3.1. The design sequence {Xn} generated by LSR-c3 under homoscedasticity
can be represented as















n=1 E (|ξn||Fn−1) <∞ a.s. and Fn−1 denotes the σ-field generated by (Xi, εi1, εi2,






(S2n − σ2) + zpσ|Xn
)
= f(Xn). It can then be shown that
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when homoscedasticity in fact holds, the sequence {Xn} generated by LSR-c3 con-
















Analogous arguments can be used to obtain the properties of SA-c3 under homoscedas-
ticity. In an unpublished manuscript, Cheung [4] showed that design sequence gener-
ated under SA-c3 is indeed strongly consistent for θ and
√
n(Xn−θ) converges weakly





















3.5.2 Asymptotic Efficiency Comparisons
As a consequence of (3.17), (3.9), (3.18) and (3.19), we can study the asymptotic
relative efficiencies of the procedures in Table 3.1 when homoscedasticity in truth
holds, i.e. σ(x) ≡ σ. To investigate the efficiency gain in using continuous instead
of dichotomized outcomes, logit-MLE is included in the comparisons. The logit-MLE











and set X̃n+1 = θ̃n. In practice, to ensure the existence and uniqueness of θ̃n, we can
adopt a two-stage approach that assigns doses initially via the stochastic approxima-




j=1 1{Yij > t0} − p
)
.
Applying results in Ying and Wu [33] gives that X̃n → θ a.s. and that if b̃ <
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2φ(zp) (σp(1− p))−1 f ′(θ), then
√
n(X̃n − θ) converges weakly to a normal distribu-




2f ′(θ)φ(zp)− σb̃p(1− p)
] , (3.20)
where φ(·) is the standard normal pdf. The asymptotic variance in (3.20) achieves
its minimum when b̃ = φ(zp) [σp(1− p)]−1 f ′(θ).
The comparisons are based on minimum asymptotic variances. Figures 3.1 (a), (b)
and (c) display the asymptotic efficiencies of case 2 and case 3 relative to case 1 with
different cohort sizes. The ratios are uniformly less than 1 and all go to 0 as p → 0
or 1. When m = 3 and p = (0.10, 0.20), the relative efficiencies against case 1 are
(0.43, 0.63), (0.45, 0.65) and (0.34, 0.52) for case 2, LSR-c3 and SA-c3, respectively.
The substantial efficiency loss is not surprising due to complete knowledge of σ under
case 1. In contrast, the efficiency loss from assuming homoscedasticity to assuming
heteroscedasticity using least square recursion is much smaller. Figure 3.1(d) shows
relative efficiency of LSR-c3 versus LSR-c2 under different cohort sizes. The efficiency
converges to [2(m− 1)(λm − 1)]−1 as p→ 0 or 1 where the ratio reaches a minimum
of 0.88 when m = 2. The efficiency improves as the cohort size m increases, and
always stays above 0.90 with m ≥ 3. The asymptotic efficiency of LSR-c2 relative
to logit-MLE is depicted in Figure 3.1 (e). When p = 0.10 and m = 3, the ratio is
1.25. As the plot shows, the efficiency gain can be considerable, especially when p is
extreme.
From these comparisons, we observe that stochastic approximation seems to be
making poor use of the data when Ui are correlated as is evident in the fact that SA-
c3 has worse efficiency then SA-c2 even when homoscedasticity holds. In contrast,
LSR-c3 uses the data much more efficiently. Another observation is that, in the
context of least square recursion, efficiency loss from parametric to nonparametric
variance estimation is small. This modest advantage of parametric estimation and
29




































































































































Figure 3.1: Asymptotic relative efficiencies under homoscedasticity with various cohort
sizes. (a), (b) and (c): case 2 and case 3 relative to case 1 (d): LSR-c2 relative to LSR-c3
(e) LSR-c2 relative to logit-MLE.
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the irreversible effect misspecification on σ(·) can have on the final estimate lead to the
conclusion that, unless there are compelling reasons, parametric assumptions on σ(·)
should be avoided. Nonparametric estimation of variance seems to be a reasonable
choice when using continuous data.
3.5.3 Simulation Studies
We conducted a series of simulation studies to compare efficiency in finite-sample
settings. The outcomes are generated with mean
M(x) =
2 [−cp + 2 log(x− θ + 1) + 1.5(x− θ)3]
1 + eθ−x
, (3.21)
variance σ2(x) ≡ 1 for x ∈ [0, 1]. We set t0 = 0 so that θ as specified in (3.21) is
the root to (3.3). We consider p = 0.1, 0.2 and θ = 0.25, 0.50, 0.75. All procedures in
the simulation make the working assumption that εij arises from a standard normal,
even though noises may be generated from other distributions to evaluate the impact
of violation of normality assumption.
To restrict the doses to [0, 1], we apply truncation to the design points. Specifically,
if θ̂n is the current design point generated by a procedure, then the next dose is set
at Xn+1 = max{min(θ̂n, 1), 0} instead of Xn+1 = θ̂n. Such truncation does not affect
the asymptotic properties of a procedure (see [14]), and is often done in practice.
However, with truncation, the sequences generated by least square recursion and
stochastic approximation may no longer be identical even under cases 1 and 2. Thus,
the simulation include all procedures in Table 3.1 as well as logit-MLE based on
dichotomized data, to which truncation was also applied. In order to investigate
the relative performance of the procedures when the tuning parameters b (for least
square recursion and stochastic approximation) and b̃ (for logit-MLE) are both well
and poorly chosen, we set b and b̃ at their respective optimal value that minimizes
the asymptotic variance as well as half of the optimal value.
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In the first set of simulations, we ran the procedures with m = 3, n = 15, and also
considered the fully sequential version of logit-MLE (denoted as logit-MLE(f)), i.e.,
m = 1 and n = 45. Each simulated trial has starting dose X1 = 0.25 or 0.50. Table
3.2 summarizes the results of the first simulation study with optimal b and b̃. Overall,
the biases are small when compared to the variances for all procedures. In line with
the asymptotic comparison, the efficiency against case 1 (assuming known σ) is quite
low for cases 2 and 3, especially when the target percentile is extreme, i.e., p = 0.1.
For least square recursion, assuming heteroscedasticity instead of homoscedasticity
yields further slight drop in efficiency; while with stochastic approximation efficiency
improves noticeably. Stochastic approximation seems to have comparable bias but
smaller variance to its least square recursion counterpart under cases 1 and 2. The
logit-MLE shows a marked efficiency loss when compared to either stochastic approx-
imation or least square recursion, with the exception of SA-c3 under some scenarios.
The fully sequential logit-MLE retrieves some information loss from the small-group
logit-MLE, but the gain in efficiency does not completely recover the loss due to the
use of dichotomised data. The impact of the starting dose X1 on the operating char-
acteristics is comparatively nuanced, although the logit-MLE tends to have smaller
variance when the starting dose X1 is closer to the target dose θ.
Results from the first set of simulations when b and b̃ are set at half the optimal
values are displayed in Table 3.3. In line with the asymptotic theory, setting the
tuning parameter to be optimal generally yields better bias and variance. The only
exception is when p = 0.1 and θ = 0.75, the logit-MLE with a low starting dose
(X1 = 0.25) has worse mean squared error when compared to Table 3.2. It is known
that logit-MLE with a large b̃ corresponds to small changes in subsequent doses;
therefore, with a finite sample size, it will have difficulty climbing to a high θ if the
starting dose is low, and can be improved with the use of a smaller b̃. Interestingly,
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using a suboptimal b improves the relative performance of SA-c3. While still inferior
to SA-c2, SA-c3 now generally has slightly smaller mean squared error than LSR-c3.
Tables 3.4 and 3.5 displays results from the second set of simulations where we
further study the effects of group sizes. Specifically, we consider designs with a bigger
group size, m = 5 and set n = 9 so that the total sample size remains 45. We also
consider random group sizes generated by permuting {2, 2, 2, 3, 3, 3, 4, 4, 5, 5, 6, 6} so
that there are n = 12 groups and a total of 45 subjects in each simulated trial.
Generally, the relative performance between stochastic approximation and least
square recursion and the relative performance among the cases within the method
follow the same patterns as in Tables 3.2 and 3.3. A bigger group size seems to have
a slightly negative effect on logit-MLE. Specifically, logit-MLE(f) seems to outperform
the small-group logit-MLE in finite sample size. Note that the asymptotic variance
of logit-MLE does not depend on group size as long as the total sample size nm is
the same. In contrast, the impact of group size on least squares recursion is relatively
small. There is in fact slight improvement in relative efficiency of case 2 and case
3 against case 1 when m = 5: this is in line with the fact that bigger group size
improves asymptotic efficiency of the least squares recursion with unknown variance.
The third simulation study aims to examine the robustness of least squares recur-
sion and stochastic approximation when εij is non-normal. While the procedures use
normality as the working assumption, we generated noises from other distributions
with mean 0 and unit variance. Tables 3.6 and 3.7 summarize the results under lo-
gistic distribution with mean 0 and scale 0.55, and t-distribution with 6 degrees of
freedom (scaled to have unit variance).
Overall, both least squares recursion procedure and stochastic approximation in-
duce larger biases under misspecified distribution, except for SA-c2 and SA-c3 with
p = 0.10 and θ = 0.25. The increased biases are still generally small when compared
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to the variances. Interestingly, assuming heteroscedasticity (case 2) seems to mitigate
the increase in bias due to misspecification, and as a result, LSR-c2 now has smaller
mean squared error then LSR-c3. It is also important to note that least squares
recursion and stochastic approximation are generally superior to the logit-MLE in
terms of mean squared error, even though the latter did not require normality to
be valid. This suggests that variability, rather than bias, is the limiting factor of
performance when sample size ranges from small to moderate. In other words, the
information retrieved via the use of continuous data outweighs the potential bias
induced by misspecification.
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Table 3.2: Properties of least square recursion, stochastic approximation and logit-MLE
with m = 3, n = 15 and the fully sequential logit-MLE(f) (m = 1, n = 45). Tuning
parameters b and b̃ equal optimal values that minimize asymptotic variances.
p θ X1 = 0.25 X1 = 0.50
bias var rmseLSR rmseSA bias var rmseLSR rmseSA
0.10 0.25 LSR-c1 -0.05 1.05 — 0.90 -0.06 1.05 — 0.90
LSR-c2 -0.09 2.11 0.50 0.45 -0.09 2.11 0.50 0.45
LSR-c3 -0.04 2.03 0.52 0.47 -0.05 2.03 0.52 0.47
SA-c1 0.05 0.95 1.11 — 0.05 0.95 1.11 —
SA-c2 0.19 1.79 0.58 0.52 0.18 1.79 0.58 0.52
SA-c3 0.23 2.22 0.46 0.42 0.23 2.22 0.46 0.42
logit-MLE -0.04 2.71 0.39 0.35 -0.12 2.38 0.44 0.40
logit-MLE(f) -0.02 2.59 0.41 0.37 -0.11 2.41 0.44 0.39
0.50 LSR-c1 0.00 1.03 — 0.99 -0.01 1.03 — 0.99
LSR-c2 -0.01 2.25 0.46 0.45 -0.01 2.25 0.46 0.45
LSR-c3 0.04 2.14 0.48 0.48 0.03 2.14 0.48 0.48
SA-c1 -0.00 1.02 1.01 — -0.01 1.02 1.01 —
SA-c2 0.01 2.14 0.48 0.48 0.01 2.14 0.48 0.48
SA-c3 0.12 2.63 0.39 0.38 0.12 2.63 0.39 0.38
logit-MLE -0.11 3.60 0.29 0.28 -0.09 3.13 0.33 0.32
logit-MLE(f) -0.09 3.39 0.30 0.30 -0.09 3.09 0.33 0.33
0.75 LSR-c1 0.10 1.04 — 0.90 0.04 1.03 — 0.92
LSR-c2 0.13 2.12 0.49 0.44 0.09 2.12 0.49 0.45
LSR-c3 0.18 2.02 0.51 0.46 0.13 2.02 0.51 0.47
SA-c1 -0.03 0.94 1.11 — -0.05 0.95 1.09 —
SA-c2 -0.15 1.84 0.57 0.51 -0.16 1.84 0.56 0.51
SA-c3 -0.01 2.20 0.48 0.43 -0.01 2.20 0.47 0.43
logit-MLE -1.35 4.96 0.15 0.14 -0.19 3.11 0.33 0.30
logit-MLE(f) -0.98 4.32 0.20 0.18 -0.15 2.96 0.35 0.32
0.20 0.25 LSR-c1 -0.03 0.81 — 0.92 -0.04 0.81 — 0.92
LSR-c2 -0.05 1.23 0.66 0.61 -0.06 1.23 0.66 0.61
LSR-c3 -0.02 1.19 0.68 0.63 -0.02 1.19 0.68 0.63
SA-c1 0.04 0.75 1.08 — 0.03 0.74 1.09 —
SA-c2 0.08 1.09 0.74 0.68 0.08 1.09 0.74 0.68
SA-c3 0.13 1.30 0.61 0.57 0.13 1.30 0.61 0.56
logit-MLE -0.04 1.59 0.51 0.47 -0.06 1.53 0.53 0.49
logit-MLE(f) -0.04 1.57 0.51 0.48 -0.07 1.58 0.51 0.47
0.50 LSR-c1 0.00 0.79 — 0.99 -0.00 0.79 — 0.99
LSR-c2 0.00 1.22 0.65 0.64 -0.00 1.22 0.65 0.64
LSR-c3 0.03 1.18 0.67 0.66 0.02 1.18 0.67 0.66
SA-c1 0.00 0.79 1.01 — -0.00 0.79 1.01 —
SA-c2 0.00 1.20 0.66 0.65 0.00 1.20 0.66 0.66
SA-c3 0.09 1.42 0.56 0.55 0.09 1.42 0.56 0.55
logit-MLE -0.00 1.84 0.43 0.43 -0.05 1.65 0.48 0.48
logit-MLE(f) 0.00 1.81 0.44 0.44 -0.05 1.68 0.47 0.47
0.75 LSR-c1 0.08 0.80 — 0.92 0.03 0.80 — 0.94
LSR-c2 0.10 1.23 0.66 0.60 0.05 1.22 0.65 0.61
LSR-c3 0.13 1.19 0.67 0.62 0.08 1.18 0.67 0.63
SA-c1 -0.01 0.74 1.09 — -0.03 0.75 1.07 —
SA-c2 -0.05 1.10 0.74 0.68 -0.07 1.10 0.72 0.68
SA-c3 0.04 1.28 0.63 0.58 0.04 1.28 0.62 0.58
logit-MLE 0.11 2.09 0.39 0.35 0.00 1.77 0.45 0.42
logit-MLE(f) 0.09 1.90 0.42 0.39 0.00 1.75 0.46 0.43
bias: bias ×10; var: variance ×102; rmseLSR: mean squared error ratio relative to LSR-c1; rmseSA:
mean squared error ratio relative to SA-c1
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Table 3.3: Properties of least square recursion, stochastic approximation and logit-MLE
with m = 3, n = 15 and the fully sequential logit-MLE(f) (m = 1, n = 45). Tuning
parameters b and b̃ equal half the optimal values that minimize asymptotic variances.
p θ X1 = 0.25 X1 = 0.50
bias var rmseLSR rmseSA bias var rmseLSR rmseSA
0.10 0.25 LSR-c1 -0.10 1.51 — 0.90 -0.10 1.52 — 0.90
LSR-c2 -0.20 2.99 0.50 0.45 -0.21 2.99 0.50 0.45
LSR-c3 -0.18 2.88 0.52 0.47 -0.19 2.88 0.52 0.47
SA-c1 0.06 1.37 1.11 — 0.06 1.37 1.11 —
SA-c2 0.25 2.59 0.57 0.52 0.25 2.59 0.58 0.52
SA-c3 0.23 2.75 0.54 0.49 0.23 2.75 0.54 0.49
logit-MLE -0.44 3.09 0.46 0.42 -0.54 3.01 0.46 0.42
logit-MLE(f) -0.35 3.19 0.46 0.41 -0.43 3.11 0.46 0.42
0.50 LSR-c1 0.00 1.48 — 1.00 0.00 1.48 — 1.00
LSR-c2 -0.01 3.33 0.45 0.45 -0.01 3.33 0.45 0.44
LSR-c3 -0.00 3.15 0.47 0.47 -0.01 3.15 0.47 0.47
SA-c1 0.00 1.48 1.00 — 0.00 1.48 1.00 —
SA-c2 0.02 3.20 0.46 0.46 0.02 3.20 0.46 0.46
SA-c3 0.08 3.35 0.44 0.44 0.08 3.35 0.44 0.44
logit-MLE -0.20 4.88 0.30 0.30 -0.43 4.27 0.33 0.33
logit-MLE(f) -0.21 4.58 0.32 0.32 -0.40 4.17 0.34 0.34
0.75 LSR-c1 0.12 1.49 — 0.91 0.09 1.48 — 0.91
LSR-c2 0.23 3.01 0.49 0.44 0.19 3.01 0.49 0.45
LSR-c3 0.24 2.88 0.51 0.46 0.20 2.88 0.51 0.47
SA-c1 -0.05 1.36 1.10 — -0.05 1.36 1.09 —
SA-c2 -0.19 2.70 0.55 0.50 -0.19 2.70 0.54 0.50
SA-c3 -0.08 2.76 0.54 0.49 -0.08 2.76 0.54 0.49
logit-MLE -0.29 4.74 0.31 0.28 -0.04 4.11 0.36 0.33
logit-MLE(f) -0.09 4.24 0.35 0.32 -0.11 4.04 0.37 0.34
0.20 0.25 LSR-c1 -0.06 1.16 — 0.93 -0.07 1.16 — 0.93
LSR-c2 -0.11 1.77 0.65 0.61 -0.12 1.78 0.65 0.60
LSR-c3 -0.10 1.72 0.67 0.62 -0.11 1.73 0.67 0.62
SA-c1 0.04 1.08 1.08 — 0.04 1.08 1.08 —
SA-c2 0.09 1.58 0.73 0.68 0.09 1.58 0.73 0.68
SA-c3 0.12 1.70 0.68 0.63 0.12 1.70 0.68 0.63
logit-MLE -0.24 2.13 0.53 0.49 -0.27 2.17 0.52 0.48
logit-MLE(f) -0.21 2.13 0.54 0.50 -0.24 2.14 0.53 0.49
0.50 LSR-c1 0.01 1.13 — 1.00 0.00 1.13 — 1.00
LSR-c2 0.00 1.77 0.64 0.64 0.00 1.77 0.64 0.64
LSR-c3 0.01 1.70 0.66 0.66 0.00 1.70 0.66 0.66
SA-c1 0.00 1.13 1.00 — 0.01 1.13 1.00 —
SA-c2 0.01 1.76 0.64 0.64 0.01 1.76 0.64 0.64
SA-c3 0.06 1.88 0.60 0.60 0.06 1.88 0.60 0.60
logit-MLE -0.15 2.37 0.47 0.47 -0.19 2.32 0.48 0.48
logit-MLE(f) -0.16 2.32 0.48 0.48 -0.17 2.33 0.48 0.48
0.75 LSR-c1 0.09 1.15 — 0.92 0.07 1.14 — 0.93
LSR-c2 0.14 1.77 0.65 0.60 0.11 1.76 0.65 0.60
LSR-c3 0.15 1.71 0.67 0.62 0.11 1.70 0.67 0.63
SA-c1 -0.03 1.07 1.08 — -0.03 1.07 1.07 —
SA-c2 -0.07 1.60 0.72 0.67 -0.07 1.60 0.71 0.67
SA-c3 -0.01 1.69 0.69 0.63 -0.01 1.69 0.68 0.63
logit-MLE 0.19 2.52 0.45 0.42 -0.01 2.34 0.49 0.46
logit-MLE(f) 0.06 2.44 0.47 0.44 -0.06 2.33 0.49 0.46
bias: bias ×10; var: variance ×102; rmseLSR: mean squared error ratio relative to LSR-c1; rmseSA:
mean squared error ratio relative to SA-c1
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Table 3.4: Properties of least square recursion, stochastic approximation and logit-
MLE with X1 = 0.25. Tuning parameters b and b̃ equal optimal values that minimize
asymptotic variances.
p θ m = 5, n = 9 Varying group sizes
bias var rmseLSR rmseSA bias var rmseLSR rmseSA
0.10 0.25 LSR-c1 -0.04 1.04 — 0.91 -0.04 1.17 — 0.90
LSR-c2 -0.06 1.94 0.53 0.48 -0.05 2.42 0.48 0.43
LSR-c3 -0.02 1.90 0.55 0.50 -0.00 2.30 0.51 0.46
SA-c1 0.04 0.94 1.10 — 0.06 1.05 1.11 —
SA-c2 0.13 1.67 0.62 0.56 0.23 2.01 0.57 0.51
SA-c3 0.15 2.09 0.49 0.45 0.29 2.55 0.44 0.40
logit-MLE -0.02 2.65 0.39 0.36 -0.03 2.71 0.43 0.39
0.50 LSR-c1 0.01 1.03 — 0.99 0.02 1.16 — 0.98
LSR-c2 0.02 2.03 0.50 0.50 0.02 2.68 0.43 0.42
LSR-c3 0.06 1.98 0.52 0.51 0.08 2.52 0.46 0.45
SA-c1 0.01 1.01 1.01 — 0.01 1.14 1.02 —
SA-c2 0.02 1.94 0.53 0.52 0.05 2.48 0.47 0.46
SA-c3 0.08 2.43 0.42 0.42 0.16 3.11 0.37 0.36
logit-MLE -0.09 3.71 0.28 0.27 -0.07 3.73 0.31 0.31
0.75 LSR-c1 0.15 1.04 — 0.88 0.14 1.18 — 0.87
LSR-c2 0.19 1.97 0.53 0.47 0.18 2.45 0.48 0.42
LSR-c3 0.23 1.92 0.54 0.48 0.23 2.32 0.51 0.44
SA-c1 0.02 0.94 1.14 — -0.01 1.05 1.15 —
SA-c2 -0.06 1.70 0.63 0.55 -0.13 2.12 0.56 0.49
SA-c3 -0.00 2.09 0.51 0.45 0.01 2.57 0.47 0.41
logit-MLE -1.57 5.26 0.14 0.12 -1.49 5.16 0.16 0.14
0.20 0.25 LSR-c1 -0.02 0.80 — 0.93 -0.02 0.91 — 0.92
LSR-c2 -0.03 1.15 0.70 0.64 -0.03 1.42 0.64 0.58
LSR-c3 0.00 1.13 0.71 0.66 0.01 1.36 0.67 0.61
SA-c1 0.03 0.74 1.08 — 0.05 0.83 1.09 —
SA-c2 0.06 1.03 0.77 0.72 0.11 1.24 0.72 0.66
SA-c3 0.08 1.23 0.65 0.60 0.16 1.50 0.59 0.54
logit-MLE -0.04 1.60 0.50 0.46 -0.02 1.57 0.58 0.53
0.50 LSR-c1 0.01 0.79 — 0.99 0.02 0.90 — 0.98
LSR-c2 0.02 1.15 0.69 0.68 0.03 1.43 0.63 0.62
LSR-c3 0.04 1.13 0.70 0.70 0.06 1.37 0.65 0.64
SA-c1 0.01 0.78 1.01 — 0.02 0.88 1.02 —
SA-c2 0.02 1.13 0.70 0.70 0.03 1.39 0.65 0.64
SA-c3 0.07 1.33 0.59 0.59 0.12 1.67 0.53 0.53
logit-MLE 0.01 1.85 0.43 0.42 0.03 1.84 0.49 0.48
0.75 LSR-c1 0.13 0.81 — 0.90 0.12 0.92 — 0.89
LSR-c2 0.15 1.16 0.69 0.62 0.14 1.43 0.64 0.57
LSR-c3 0.17 1.14 0.70 0.63 0.18 1.37 0.66 0.59
SA-c1 0.04 0.74 1.11 — 0.01 0.83 1.12 —
SA-c2 0.02 1.03 0.80 0.72 -0.03 1.26 0.74 0.66
SA-c3 0.05 1.22 0.67 0.60 0.05 1.49 0.62 0.55
logit-MLE 0.09 2.37 0.35 0.31 0.09 2.23 0.42 0.37
bias: bias ×10; var: variance ×102; rmseLSR: mean squared error ratio relative to LSR-c1; rmseSA:
mean squared error ratio relative to SA-c1
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Table 3.5: Properties of least square recursion, stochastic approximation and logit-
MLE with X1 = 0.25. Tuning parameters b and b̃ equal half the optimal values that
minimize asymptotic variances.
p θ m = 5, n = 9 Varying group sizes
bias var rmseLSR rmseSA bias var rmseLSR rmseSA
0.10 0.25 LSR-c1 -0.15 1.55 — 0.90 -0.11 1.73 — 0.89
LSR-c2 -0.22 2.80 0.55 0.50 -0.20 3.40 0.51 0.45
LSR-c3 -0.21 2.74 0.57 0.51 -0.17 3.24 0.54 0.48
SA-c1 0.02 1.41 1.11 — 0.07 1.56 1.12 —
SA-c2 0.16 2.46 0.63 0.57 0.31 2.93 0.58 0.52
SA-c3 0.16 2.77 0.56 0.50 0.31 3.34 0.51 0.45
logit-MLE -0.56 3.12 0.46 0.41 -0.48 3.32 0.49 0.44
0.50 LSR-c1 -0.01 1.53 — 1.00 0.01 1.72 — 0.99
LSR-c2 0.00 3.03 0.50 0.50 -0.00 4.04 0.43 0.42
LSR-c3 0.01 2.96 0.52 0.51 0.01 3.81 0.45 0.45
SA-c1 -0.02 1.52 1.00 — 0.01 1.71 1.01 —
SA-c2 0.01 2.94 0.52 0.52 0.04 3.74 0.46 0.46
SA-c3 0.05 3.30 0.46 0.46 0.13 4.17 0.41 0.41
logit-MLE -0.22 5.17 0.29 0.29 -0.22 5.26 0.32 0.32
0.75 LSR-c1 0.18 1.57 — 0.89 0.17 1.75 — 0.88
LSR-c2 0.30 2.80 0.55 0.49 0.28 3.48 0.50 0.44
LSR-c3 0.31 2.74 0.56 0.50 0.30 3.33 0.52 0.46
SA-c1 -0.05 1.42 1.13 — -0.05 1.56 1.14 —
SA-c2 -0.13 2.52 0.63 0.56 -0.21 3.15 0.56 0.49
SA-c3 -0.07 2.78 0.58 0.51 -0.07 3.39 0.52 0.46
logit-MLE -0.48 5.25 0.29 0.26 -0.34 5.05 0.34 0.30
0.20 0.25 LSR-c1 -0.10 1.19 — 0.92 -0.08 1.35 — 0.91
LSR-c2 -0.13 1.70 0.70 0.65 -0.12 2.07 0.65 0.59
LSR-c3 -0.13 1.68 0.71 0.66 -0.11 1.99 0.67 0.62
SA-c1 0.01 1.11 1.08 — 0.05 1.23 1.09 —
SA-c2 0.05 1.53 0.78 0.72 0.12 1.80 0.74 0.68
SA-c3 0.08 1.72 0.70 0.64 0.17 2.05 0.65 0.60
logit-MLE -0.34 2.16 0.53 0.49 -0.29 2.18 0.60 0.55
0.50 LSR-c1 -0.01 1.16 — 1.00 0.01 1.31 — 1.00
LSR-c2 0.01 1.67 0.69 0.69 0.01 2.13 0.62 0.62
LSR-c3 0.01 1.65 0.71 0.70 0.01 2.04 0.64 0.64
SA-c1 -0.02 1.16 1.00 — 0.01 1.31 1.00 —
SA-c2 -0.00 1.66 0.70 0.70 0.01 2.09 0.63 0.63
SA-c3 0.03 1.86 0.62 0.62 0.09 2.34 0.56 0.56
logit-MLE -0.19 2.51 0.46 0.46 -0.18 2.54 0.51 0.51
0.75 LSR-c1 0.14 1.21 — 0.90 0.14 1.36 — 0.89
LSR-c2 0.20 1.71 0.70 0.63 0.20 2.11 0.64 0.57
LSR-c3 0.21 1.69 0.71 0.64 0.20 2.04 0.66 0.59
SA-c1 -0.03 1.11 1.11 — -0.03 1.23 1.12 —
SA-c2 -0.05 1.53 0.80 0.72 -0.08 1.88 0.73 0.65
SA-c3 -0.01 1.70 0.72 0.65 -0.00 2.06 0.67 0.60
logit-MLE 0.28 2.66 0.45 0.41 0.22 2.67 0.51 0.45
bias: bias ×10; var: variance ×102; rmseLSR: mean squared error ratio relative to LSR-c1; rmseSA:
mean squared error ratio relative to SA-c1
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Table 3.6: Properties of least square recursion, stochastic approximation and logit-MLE
(m = 3, n = 15) and the fully sequential logit-MLE(f) (m = 1, n = 45) with X1 = 0.25.
Tuning parameters b and b̃ equal the optimal values.
p θ Logistic t6
bias var rmseLSR rmseSA bias var rmseLSR rmseSA
0.10 0.25 LSR-c1 -0.50 1.00 — 0.82 -0.74 0.90 — 0.80
LSR-c2 -0.30 2.11 0.57 0.46 -0.40 2.02 0.67 0.53
LSR-c3 -0.40 2.10 0.55 0.45 -0.54 2.02 0.62 0.50
SA-c1 -0.37 0.88 1.22 — -0.60 0.79 1.25 —
SA-c2 0.02 1.75 0.71 0.58 -0.07 1.66 0.87 0.69
SA-c3 -0.10 2.23 0.56 0.46 -0.24 2.17 0.65 0.52
logit-MLE -0.04 2.74 0.46 0.37 -0.08 2.57 0.56 0.45
logit-MLE(f) -0.06 2.64 0.47 0.39 -0.11 2.56 0.56 0.45
0.50 LSR-c1 -0.45 1.01 — 0.99 -0.69 0.93 — 0.98
LSR-c2 -0.25 2.40 0.49 0.48 -0.36 2.36 0.57 0.55
LSR-c3 -0.37 2.49 0.46 0.46 -0.55 2.58 0.49 0.48
SA-c1 -0.45 0.99 1.02 — -0.68 0.91 1.02 —
SA-c2 -0.19 2.23 0.53 0.53 -0.28 2.16 0.63 0.62
SA-c3 -0.27 2.92 0.40 0.40 -0.43 3.00 0.44 0.43
logit-MLE -0.18 3.71 0.32 0.32 -0.19 3.68 0.38 0.37
logit-MLE(f) -0.18 3.62 0.33 0.33 -0.16 3.47 0.40 0.40
0.75 LSR-c1 -0.36 1.03 — 0.99 -0.60 0.95 — 1.03
LSR-c2 -0.09 2.30 0.50 0.50 -0.20 2.31 0.56 0.58
LSR-c3 -0.21 2.40 0.47 0.47 -0.39 2.57 0.48 0.50
SA-c1 -0.45 0.95 1.01 — -0.69 0.88 0.97 —
SA-c2 -0.32 2.02 0.55 0.54 -0.40 2.05 0.59 0.61
SA-c3 -0.37 2.61 0.42 0.42 -0.53 2.82 0.42 0.44
logit-MLE -1.19 4.89 0.18 0.18 -1.22 4.89 0.21 0.21
logit-MLE(f) -0.90 4.38 0.22 0.22 -0.95 4.36 0.25 0.26
0.20 0.25 LSR-c1 -0.47 0.78 — 0.85 -0.62 0.72 — 0.84
LSR-c2 -0.35 1.23 0.74 0.63 -0.43 1.17 0.82 0.69
LSR-c3 -0.42 1.24 0.71 0.60 -0.53 1.20 0.75 0.63
SA-c1 -0.39 0.70 1.18 — -0.53 0.65 1.19 —
SA-c2 -0.19 1.05 0.92 0.78 -0.26 0.99 1.05 0.88
SA-c3 -0.25 1.28 0.75 0.63 -0.35 1.25 0.81 0.68
logit-MLE -0.08 1.47 0.68 0.58 -0.11 1.35 0.82 0.68
logit-MLE(f) -0.09 1.46 0.68 0.58 -0.11 1.34 0.82 0.69
0.50 LSR-c1 -0.44 0.78 — 0.99 -0.58 0.72 — 0.99
LSR-c2 -0.31 1.27 0.71 0.70 -0.39 1.22 0.77 0.76
LSR-c3 -0.38 1.30 0.67 0.66 -0.50 1.33 0.67 0.66
SA-c1 -0.43 0.77 1.01 — -0.58 0.71 1.02 —
SA-c2 -0.29 1.23 0.73 0.73 -0.36 1.17 0.82 0.80
SA-c3 -0.32 1.53 0.59 0.59 -0.43 1.56 0.61 0.60
logit-MLE -0.05 1.72 0.56 0.55 -0.05 1.58 0.67 0.66
logit-MLE(f) -0.08 1.67 0.58 0.57 -0.10 1.52 0.69 0.68
0.75 LSR-c1 -0.36 0.79 — 1.00 -0.51 0.74 — 1.02
LSR-c2 -0.22 1.28 0.69 0.70 -0.29 1.23 0.76 0.77
LSR-c3 -0.28 1.31 0.66 0.66 -0.40 1.33 0.67 0.68
SA-c1 -0.43 0.74 1.00 — -0.57 0.69 0.98 —
SA-c2 -0.32 1.18 0.72 0.72 -0.39 1.14 0.77 0.79
SA-c3 -0.35 1.45 0.59 0.59 -0.46 1.51 0.58 0.59
logit-MLE 0.04 2.06 0.45 0.45 0.04 1.98 0.50 0.52
logit-MLE(f) 0.05 1.85 0.50 0.50 0.04 1.76 0.57 0.58
bias: bias ×10; var: variance ×102; rmseLSR: mean squared error ratio relative to LSR-c1; rmseSA:
mean squared error ratio relative to SA-c1
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Table 3.7: Properties of least square recursion, stochastic approximation, logit-MLE
(m = 3, n = 15) and the fully sequential logit-MLE(f) (m = 1, n = 45) with X1 = 0.25.
Tuning parameters b and b̃ equal half the optimal values.
p θ Logistic t6
bias var rmseLSR rmseSA bias var rmseLSR rmseSA
0.10 0.25 LSR-c1 -0.56 1.43 — 0.79 -0.81 1.29 — 0.77
LSR-c2 -0.40 2.87 0.58 0.46 -0.50 2.78 0.64 0.50
LSR-c3 -0.53 2.79 0.57 0.45 -0.68 2.70 0.62 0.48
SA-c1 -0.36 1.26 1.26 — -0.58 1.16 1.30 —
SA-c2 0.11 2.42 0.72 0.57 0.02 2.37 0.82 0.63
SA-c3 -0.09 2.74 0.64 0.50 -0.21 2.69 0.71 0.55
logit-MLE -0.49 3.16 0.51 0.41 -0.52 3.12 0.58 0.44
logit-MLE(f) -0.43 3.11 0.53 0.42 -0.46 3.04 0.60 0.46
0.50 LSR-c1 -0.46 1.45 — 0.99 -0.70 1.40 — 0.99
LSR-c2 -0.26 3.51 0.46 0.46 -0.38 3.53 0.51 0.51
LSR-c3 -0.43 3.63 0.44 0.43 -0.62 3.75 0.46 0.45
SA-c1 -0.45 1.45 1.01 — -0.70 1.39 1.01 —
SA-c2 -0.17 3.25 0.51 0.50 -0.27 3.23 0.57 0.57
SA-c3 -0.30 3.64 0.44 0.44 -0.46 3.75 0.48 0.47
logit-MLE -0.31 5.06 0.32 0.32 -0.36 4.91 0.38 0.37
logit-MLE(f) -0.37 4.76 0.34 0.34 -0.35 4.61 0.40 0.40
0.75 LSR-c1 -0.37 1.50 — 0.99 -0.63 1.43 — 1.02
LSR-c2 -0.02 3.29 0.50 0.49 -0.15 3.36 0.54 0.55
LSR-c3 -0.18 3.42 0.47 0.47 -0.39 3.71 0.47 0.48
SA-c1 -0.48 1.38 1.01 — -0.72 1.35 0.98 —
SA-c2 -0.36 2.91 0.54 0.53 -0.43 3.03 0.57 0.58
SA-c3 -0.43 3.20 0.48 0.48 -0.58 3.45 0.48 0.49
logit-MLE -0.27 4.92 0.33 0.32 -0.35 4.90 0.36 0.37
logit-MLE(f) -0.12 4.50 0.36 0.36 -0.15 4.46 0.41 0.42
0.20 0.25 LSR-c1 -0.52 1.12 — 0.83 -0.68 1.05 — 0.81
LSR-c2 -0.43 1.73 0.72 0.60 -0.51 1.66 0.78 0.64
LSR-c3 -0.52 1.72 0.70 0.58 -0.64 1.67 0.72 0.59
SA-c1 -0.38 1.00 1.21 — -0.53 0.95 1.23 —
SA-c2 -0.16 1.47 0.93 0.77 -0.23 1.41 1.03 0.84
SA-c3 -0.25 1.66 0.81 0.67 -0.35 1.63 0.86 0.70
logit-MLE -0.30 1.98 0.67 0.55 -0.32 1.92 0.74 0.61
logit-MLE(f) -0.28 1.94 0.69 0.57 -0.28 1.90 0.76 0.62
0.50 LSR-c1 -0.44 1.11 — 1.00 -0.60 1.07 — 1.00
LSR-c2 -0.32 1.83 0.68 0.67 -0.40 1.81 0.72 0.72
LSR-c3 -0.42 1.87 0.64 0.64 -0.56 1.95 0.63 0.63
SA-c1 -0.44 1.11 1.00 — -0.60 1.07 1.00 —
SA-c2 -0.29 1.79 0.70 0.69 -0.37 1.76 0.75 0.75
SA-c3 -0.36 1.99 0.62 0.61 -0.47 2.05 0.63 0.63
logit-MLE -0.23 2.26 0.56 0.56 -0.25 2.18 0.64 0.64
logit-MLE(f) -0.23 2.15 0.59 0.59 -0.25 2.04 0.68 0.68
0.75 LSR-c1 -0.38 1.14 — 1.00 -0.54 1.10 — 1.02
LSR-c2 -0.20 1.85 0.68 0.68 -0.30 1.84 0.72 0.74
LSR-c3 -0.30 1.89 0.65 0.65 -0.45 1.96 0.64 0.66
SA-c1 -0.46 1.08 1.00 — -0.61 1.05 0.98 —
SA-c2 -0.34 1.71 0.70 0.70 -0.41 1.73 0.73 0.75
SA-c3 -0.40 1.88 0.63 0.63 -0.51 1.98 0.62 0.64
logit-MLE 0.10 2.47 0.52 0.52 0.07 2.39 0.58 0.59
logit-MLE(f) -0.04 2.29 0.56 0.56 -0.06 2.20 0.63 0.64
bias: bias ×10; var: variance ×102; rmseLSR: mean squared error ratio relative to LSR-c1; rmseSA:





We have seen that in sequential dose finding designs based on continuous data, there
is strong reason for nonparametric estimation of σ(·). In the last chapter, σ(xn) is
estimated by [E (Sn/σ(Xn))]
−1 Sn, which utilizes data from cohort n only. In this
chapter, we propose better estimates by pooling observations across cohorts in hopes
of improving upon the current designs.
We retain the setting and notations defined in Section 3.2. The objective remains
to identify, from a set of discrete doses labelled {1, . . . , K}, either ν1 or ν2, defined in
(2.2) and (3.4), respectively. In this chapter, the procedure with recursion (3.10) and
Vn = Un + β(X
∗
n −Xn) = Ȳn + cp [E (Sn/σ(Xn))]
−1 Sn + β(X
∗
n −Xn) is referred to as
SAVOR and the procedure with recursion (3.16) and Vin = Vi as LSRVO. Note that
under this definition, the two procedures are equivalent.
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4.2 The Procedures
Before introducing the estimators, it is necessary to introduce a few more notations
first. Let nkn =
∑n
l=1 1{Xl = k}, Ỹkn = (mnkn)−1
∑n





l=1 1{Xl = k}Ȳl. In words, after inclusion of n cohorts, nkn is the number of
cohorts assigned to dose level k and Ỹkn the average of the all continuous outcomes
from those cohorts. To incorporate all available data in estimation of σ(·), a natural
extension of the current estimator is to pool the sample standard deviations from
cohorts given the same dose. It turns out, however, that this approach provides no
improvement at all.
Proposition 4.1. Define Vin = Ȳi + cp
∑K








l=1 1{Xl = k}Sl
nkn
. (4.1)
Then the sequence {X∗n} generated by recursion (3.16) is equivalent to LSRVO.
It can be inferred from Proposition 4.1 that pooling sample standard deviations is
not an efficient way of utilizing the data and better estimators need to be proposed. To
this end, we define the following three estimators for each dose level k ∈ {1, . . . , K}:
σ̃2kn ≡
∑n


















Table 4.1: Summary of virtual observation recursions









Vin = Uin + β(X
∗
i −Xi) Vn = Un + β(X∗n −Xn)































Uin = Ȳi + cp
∑K
k=1 σ̌kn1{Xi = k} Un = Ȳn + cp
∑K
k=1 σ̌kn1{Xn = k}





Uin = Ȳi + cp
∑K
k=1 σ̃kn1{Xi = k} Un = Ȳn + cp
∑K
k=1 σ̃kn1{Xn = k}







Uin = Ȳi + cp
∑K
k=1 σ̄kn1{Xi = k} Un = Ȳn + cp
∑K
k=1 σ̄kn1{Xn = k}







Uin = Ȳi + cp
∑K
k=1 σ̂kn1{Xi = k} Un = Ȳn + cp
∑K
k=1 σ̂kn1{Xn = k}
43
The estimator σ̃2kn estimates σ
2(k) by averaging sample variances from cohorts
given dose k, while σ̄2kn and σ̂
2
kn view all patients with dose k as if they belong
to one cohort then estimate σ2(k) by the sample variance and maximum likelihood
estimator, respectively. Each of the new estimators can be incorporated into SAVOR
by changing the definition of the virtual observation Vn in recursion (3.10). The
procedures using estimators (4.1), (4.2), (4.3), (4.4) will be respectively denoted as
SAVOR-A, -B, -C and -D. Similarly, through redefining Vin in (3.16), LSRVO can
be extended to accommodate these estimators. LSRVO with estimators (4.1), (4.2),
(4.3), (4.4) will be denoted as LSRVO-A, -B, -C and -D, respectively. Table 4.1
summarizes the virtual observation recursions and the name they shall be referred to.
To illustrate how the new estimators operate, Table 4.2 displays the dose assign-
ment, continuous outcomes, estimates of σ(·) and virtual observations of a simu-
lated trial using LSRVO-D. In this example, K = 5, p = 0.1, t0 = 4.81, m = 3,
n = 11 and dose assignment follows a two-stage design with initial dose sequence
{1, 2, 3, 3, 4, 4, 4, 5, 5, 5, 5}. The tuning parameters are b = β = 0.30. Noises are as-
sumed to be standard normal so cp = 1.282. As can be seen, no outcome exceeds t0
in the first 5 cohorts thus dose assignment up to cohort 6 are dictated by the initial
dose sequence and X∗i = Xi for i = 1, . . . , 6. After the occurrence of the first toxicity
in cohort 6, (Y61 = 5.883 > 4.81), dose assignment switches to LSRVO-D and
X∗7 =
1 + 2 + · · ·+ 4
6
−(4.076− 4.81) + (4.691− 4.81) + · · ·+ (5.669− 4.81)
6× 0.30
= 2.711.
This gives X7 = C(X
∗
7 ) = 3. Throughout the trial, estimates of σ(k) and virtual
observation of a cohort assigned dose level k change every time a new cohort is
assigned dose k. For example, at the time of the switch (after inclusion of 6 cohorts),









Table 4.2: A simulated trial using LSRVO-D with two-stage design
n 1 2 3 4 5 6 7 8 9 10 11 12
Xn 1 2 3 3 4 4 3 3 3 4 3 3
X∗n 1 2 3 3 4 4 2.711 3.011 3.463 3.535 3.364 3.317
Yn1 2.391 3.321 4.055 3.219 4.549 5.883 4.277 3.429 3.053 4.311 4.023 -
Yn2 2.668 3.373 2.463 4.759 4.270 4.642 3.194 2.684 2.074 3.068 3.358 -
Yn3 4.168 4.781 2.996 3.962 3.628 2.271 2.645 2.958 4.403 5.370 4.456 -
Ȳn 3.076 3.825 3.172 3.980 4.149 4.265 3.372 3.023 3.177 4.249 3.946 -
σ̂1n 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 -
σ̂2n - 0.676 0.676 0.676 0.676 0.676 0.676 0.676 0.676 0.676 0.676 -
σ̂3n - - 0.662 0.762 0.762 0.762 0.741 0.693 0.757 0.757 0.749 -
σ̂4n - - - - 0.385 1.095 1.095 1.095 1.095 1.047 1.047 -
σ̂5n - - - - - - - - - - - -
V1n 4.076 4.076 4.076 4.076 4.076 4.076 4.076 4.076 4.076 4.076 4.076 -
V2n - 4.691 4.691 4.691 4.691 4.691 4.691 4.691 4.691 4.691 4.691 -
V3n - - 4.020 4.148 4.148 4.148 4.121 4.059 4.142 4.142 4.132 -
V4n - - - 4.956 4.956 4.956 4.930 4.868 4.950 4.950 4.940 -
V5n - - - - 4.643 5.553 5.553 5.553 5.553 5.490 5.490 -
V6n - - - - - 5.669 5.669 5.669 5.669 5.607 5.607 -
V7n - - - - - - 4.235 4.173 4.255 4.255 4.246 -
V8n - - - - - - - 3.914 3.997 3.997 3.987 -
V9n - - - - - - - - 4.286 4.286 4.276 -
V10,n - - - - - - - - - 5.451 5.451 -
V11,n - - - - - - - - - - 5.015 -






This estimate is used in the calculation of the virtual observations for both cohorts
3 and 4. For instance, V36 = Ȳ3+cpσ̂36+β(X
∗
3−X3) = 3.172+1.282×0.762+0 = 4.148.
At the end of the trial, outcomes from all cohorts assigned dose level 3 are used in
estimating σ(3) which is now σ̂3,11 = 0.749. This estimator in turn is used in the
calculation of virtual observations V3,11, V4,11, V7,11, V8,11, V9,11, and V11,11. Similarly,
the final estimate of σ(4) is based on all cohorts given dose level 4 (cohorts 5, 6 and
10) and σ̂4,11 is used to form virtual observations from these cohorts. Notice that only
one cohort each is assigned to dose levels 1 and 2. Therefore estimates for these two
dose levels remain the same throughout the trial as are the virtual observations. The
final recommended dose is dose level 3 since X∗12 = 3.317.
As a comparison, Table 4.3 a trial using SAVOR-D simulated under the same
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Table 4.3: A simulated trial using SAVOR-D with a two-stage design
n 1 2 3 4 5 6 7 8 9 10 11 12
Xn 1 2 3 3 4 4 3 3 4 4 3 3
X∗n 1 2 3 3 4 4 3.288 3.480 3.796 3.716 3.479 3.431
Yn1 2.391 3.321 4.055 3.219 4.549 5.883 4.277 3.429 3.562 4.311 4.023 -
Yn2 2.668 3.373 2.463 4.759 4.270 4.642 3.194 2.684 2.540 3.068 3.358 -
Yn3 4.168 4.781 2.996 3.962 3.628 2.271 2.645 2.958 4.969 5.370 4.456 -
Ȳn 3.076 3.825 3.172 3.980 4.149 4.265 3.372 3.023 3.690 4.249 3.946 -
σ̂1n 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 0.781 -
σ̂2n - 0.676 0.676 0.676 0.676 0.676 0.676 0.676 0.676 0.676 0.676 -
σ̂3n - - 0.662 0.762 0.762 0.762 0.741 0.693 0.693 0.693 0.689 -
σ̂4n - - - - 0.385 1.095 1.095 1.095 1.091 1.059 1.059 -
σ̂51n - - - - - - - - - - - -
Vn 4.076 4.691 4.020 4.956 4.643 5.669 4.408 4.055 5.027 5.522 4.972 -
settings. Now the virtual observations are a single sequence instead of triangle arrays.
The estimators of σ(k) are still based on all available data. However, the most
current estimator is used to calculate virtual observation of the latest cohort only.
For example, at the end of the trial, the estimate for σ(3) is σ̂3,11 = 0.689 which is
based on outcomes from cohorts 3, 4, 7, 8 and 11. This estimator is used to form
V11 = Ȳ11 + cpσ̂3,11 + β(X
∗
11−X11) = 3.946 + 1.282× 0.689 + 0.30(3.479− 3) = 4.972.
The final recommended dose is also level 3.
Some comments are in order. First, it is not difficult to imagine that for pro-
cedures using the same estimator, the performance of least square recursion based
procedure will be superior to its stochastic approximation based counterpart. As was
demonstrated in the above examples, at any time during the trial and for every cohort,
σ(·) is always estimated by the most up-to-date estimators in LSR-based procedures.
In contrast, in SA-based procedures, only the most recent cohort benefits from the
latest estimate. This feature of more efficient use of data is shared by all LSR-based
methods and was manifested in the superiority of LSR-c3 over SA-c3 in Section 3.5.
Second, within the cohorts of procedures using the same recursion, we can con-
jecture on the relative performances of the four estimators. It would be reasonable
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to expect that procedure with σ̌kn will have the worst and the ones with σ̄kn and σ̂kn
the best performances with the latter two having equivalent asymptotic properties.
Combined with the first observation means that we would expect LSRVO-B, LSRVO-
C and LSRVO-D all to improve upon LSRVO. On the other hand, SAVOR-A will be
inferior to SAVOR and while we can speculate on the the relative performances of
SAVOR-B, SAVOR-C and SAVOR-D among themselves, their relative performances
to SAVOR are more difficult to predict.
4.3 Theoretical Properties
This section states some large sample properties of the proposed procedures. The
proofs are collected in Appendix B.1. Let ε̄n = m
−1∑m
j=1 εnj and Fn−1 be the σ-field
generated by (X∗i , εi1, εi2, . . . , εim) for i = 1, . . . , n− 1.
Convergence properties under the new estimators do not trivially inherit those
under the original estimator. To establish convergence results when using the new
estimators, we start with a key transformation:
Lemma 4.1. The sequences {X∗n} generated by LSRVO-B, LSRVO-C, LSRVO-D,







(h(X∗n) + en − t0) + ξn, (4.5)
where E(en | Fn−1) = 0 and
∑∞
n=1E(|ξn| | Fn−1) <∞ a.s.
Recursion (4.5) can be viewed as a Robbins-Monro recursion with mean function
h(·), target t0, errors en’s and biases ξn’s.
The next result shows that under the same conditions on β as stated in Cheung
and Elkind [9], recursion (4.5) has the similar convergence properties as SAVOR and
LSRVO (recall G(ck) = 1− π(k) and Bk = 2σ(k)|ck − cp|).
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Theorem 4.1. Let {Xn} be the design sequence generated by (4.5).
(i) If Bν1 < β < mink 6=ν1 Bk then Xn = ν1 eventually with probability one
(ii) If β < mink Bk then P (Xn ∈ {ν1 − 1, ν1, ν1 + 1} eventually) = 1.
If consistency condition in Theorem 4.1 (i) holds, then the sequence of assigned
doses {X∗n} generated by (4.5) can be shown to be asymptotically normal. Admittedly,
the assigned doses exist only on a conceptual scale. However, as we shall see later,
knowing the asymptotic variance of {X∗n} can facilitate the calibration of the tuning
parameter b.
Theorem 4.2. Assume the consistency conditions in Theorem 4.1 (i) hold and b <
2β. Let θβ the unique root to h(x) = t0, u1 = V ar (S
2
n/σ






2(Xn)), u4 = Eε̄
3





2(Xn)) and u6 = E (ε̄nSn/σ(Xn)).
(i) For LSR-based procedures
√
















u1 +mu2 + 2(m− 1)u5
)
+ cp ((m− 1)u3 +mu4)
with LSRVO-C and LSRVO-D.
(ii) For SA-based procedures,
√






































u1 +mu2 + 2(m− 1)u5
)
+ cp ((m− 1)u3 +mu4)
with SAVOR-C and SAVOR-D.
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Figure 4.1: Left panel: asymptotic efficiency of LSRVO-B, LSRVO-C and LSRVO-D rela-
tive to LSRVO under standard normal noise. Right panel: Asymptotic efficiency of SAVOR-
A, SAVOR-B, SAVOR-C and SAVOR-D relative to SAVOR under standard normal noise.
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The asymptotic variances are minimized at b = β for LSR-based procedures and
at b = 2/(1 +
√
1 + 2κ)β for SA-based procedures. If G is standard normal then,
u1 =
2
m−1 , u2 =
2
m2




is defined in (3.8). Table C.1 summarizes the asymptotic variances of the procedures
when G is standard normal.
The asymptotic efficiencies of LSRVO-B, LSRVO-C and LSRVO-D relative to
LSRVO are shown in left panel of Figure 4.1, assuming standard normal noise and
the same b for all procedures. The ratios are uniformly greater than 1. Using σ̄kn
or σ̂kn offers marked improvement over the original estimator that increases as p
becomes more extreme. In contrast, the efficiency gain from σ̃kn is in general much
more modest. When p = 0.1 and m = 3, as is the case in NeuSTART, efficiency is
1.288 for LSRVO-C and LSRVO-D, compared to LSRVO-B’s 1.051.
Retaining the assumption of standard normal noise, the asymptotic efficiencies
of SAVOR-A, SAVOR-B, SAVOR-C and SAVOR-D relative to SAVOR are depicted
in right panel of Figure 4.1. The comparison are based on minimum asymptotic
variances, that is, we assume b = β for SAVOR and b = 2/(1 +
√
1 + 2κ)β for the
other four procedures. Except with SAVOR-C and SAVOR-D when m = 2, the
ratios only become larger 1 when p becomes extreme. When p = 0.1 and m = 3, the
efficiencies are 0.755 for SAVOR-A, 0.796 for SAVOR-B, and 0.996 for SAVOR-C and
SAVOR-D.
4.4 Application
We conducted a series of simulations in the context of NeuSTART to compare the
operating characteristics of the procedures listed in Table 4.1. To emphasize the
advantage of utilizing continuous outcomes, results from the CRM are also presented.
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4.4.1 Simulation Setup
Five toxicity scenarios were considered. In the ith scenario, dose level i has DLT
probability of 10% and is therefore the target dose (cf. Table C.2). With this setup,
θ = ν1 = ν2 and Condition 3.5 is satisfied. The trial size is m = 3 and n = 11.
The same two-stage design adopted in NeuSTART was implemented (cf. Table 2.1).
Virtual observations recursions (or the CRM) took over dose assignment in the sec-
ond stage either after occurrence of the first toxicity or after inclusion of 11 cohorts
in the event that no toxicity occurred during the first stage. Thus, the final esti-
mate was always procedure based. Restriction on dose skipping in escalation and
dose escalation immediately after a toxicity was enforced. For virtual observation





instead of X∗n+1. Dose de-escalation was unre-
stricted. One important implication of the two-stage design and the dose escalation
restriction is that sequences generated by SAVOR and LSRVO are no longer identical.
Thus, results from both recursions are presented.
For the CRM, dose-toxicity model was assumed to be empiric (2.3). Thus for dose
k, the toxicity probability was modeled as d
exp(a)
k , where dk is the numeric label and
a is a priori normal with mean 0 and variance 1.34. Calibration of initial guesses of
probabilities of DLT in the CRM was done according to the approach proposed by
Lee and Cheung [18]. Finally, all simulations were done in R [24] and simulations of
the CRM was carried out with the ‘dfcrm’ package [7].
4.4.2 Generating Continuous Outcomes
Table 4.4 displays the liver function data of each dose level from NeuSTART. The
data suggest a monotone mean-variance relationship, that is, the variance increases
with dose as the mean increases. To estimate the relationship, the standard deviations
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Table 4.4: Summary of liver function data in NeuSTART
Dose level Number of Number of toxicity log(peak ALT)
patients patients Mean STD
1 3 0 3.24 0.23
2 10 0 3.25 0.42
3 12 2 3.78 0.72
4 8 0 3.42 0.54
5 0 – – –
were transformed by the function s(x) = ex
4
then regressed against sample means.
The fitted line has a slope of 0.55. Left panel of Figure 4.2 shows that this particular
mean-variance relationship fits the data well. Finally, Q–Q plot (right panel of Figure
4.2) suggests that assuming the noises εij to be standard normal is reasonable.
To generate continuous outcomes, in each scenario, M(θ) was fixed to be 3.63, the
estimated mean log(ALT) for dose levels 3 and 4 from isotonic regression [9]. The
standard deviation at the target dose was determined by solving for f(ν) = log(123).












where Φ is the distribution function of standard normal. Table C.2 displays the
probability of DLT, M(k) and σ(k) at each dose level of the five scenarios used in the
simulations.
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Figure 4.2: Left: Sample standard deviation of log(peak ALT) transformed by func-
tion s(·) against sample mean. Right: Normal Q-Q plot of standardized residuals
4.4.3 Design Calibration
Having specified the model for the continuous outcomes, we next consider the choice
of β and b. To simplify the process, b was fixed at the optimal value in terms of
minimizing the asymptotic variance and we focused on calibration of β. Based on our
setup, consistency condition in Theorem 4.1 (i) stipulates that β should be between
0 and 0.83. For each virtual observation recursion, we calibrated β in the following
manner:
1. Iterate β from 0.08 to 0.83 with a grid of 0.01. For all LSR-based procedures and
SAVOR, set b = β; for the other SA-based procedures, set b = 2/(1+
√
1 + 2κ)β.
2. For each β, perform simulations 5000 times under each scenario and obtain the
proportion of correct selection (PCS).
3. Choose the β that maximizes the average PCS across the 5 scenarios.
Figure 4.3 displays the calibration results. For LSR-based procedures, LSRVO-C
offers consistent and marked improvement over LSRVO in terms of correctly selecting
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Figure 4.3: Average proportion of selecting ν1 against β. The dot on each line
indicates maximum average PCS. The average PCS of the continual reassessment
method is indicated.
ν1 on average. In contrast, LSRVO-B and LSRVO-D are superior to the original only
when β becomes larger. The maximum average selection probabilities are 0.70, 0.71,
0.74, 0.75 and the corresponding β are 0.38, 0.40, 0.42, 0.48 for LSRVO, LSRVO-B,
LSRVO-C and LSRVO-D, respectively. As a comparison, the average PCS of the
continual reassessment method is 0.64.
Calibration results of the SA-based procedures show that, compared to SAVOR,
SAVOR-C and SAVOR-D perform slightly better overall while SAVOR-B is worse.
The maximum average selection probabilities are 0.67, 0.65, 0.67, 0.69, 0.69 at (β, b) =
(0.39, 0.39), (0.49, 0.28), (0.51, 0.30), (0.41, 0.27), and (0.38, 0.25) for SAVOR, SAVOR-
A, SAVOR-B, SAVOR-C and SAVOR-D, respectively.
4.4.4 Results
Table 4.5 shows the selection proportions, average number of patients treated at
each dose, average number of patients treated at doses above the target dose ν1,
and the average number of toxicity when each virtual observation recursion is run
at its respective optimal β. Among the four LSR-based procedures, none of the
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new estimators outperforms the original under scenario 1 in terms of PCS. However,
the probabilities are all well over 0.80. The patterns under scenarios 2 to 4 are
similar in that LSRVO-B does marginally better than the original while LSRVO-C
and LSRVO-D both provide appreciably higher selection proportion. Under scenario
5, the new estimators offer a noticeable improvement. In terms of safety, LSRVO-D
is more aggressive with a higher number of patients treated above the target and
more frequent recommendations of an unsafe dose than both LSRVO and LSRVO-C.
However, this aggressiveness is limited to no more than one level above the target
and the number of total toxicities are comparable for all estimators across scenarios.
Among the five SA-based procedures, none of the new estimators improves upon
the original under scenario 1 and all do under scenario 5 with SAVOR-D having the
most extreme performance. Under scenarios 2 to 4, the four estimators are compa-
rable. A comparison between SAVOR-C and SAVOR-D, the two with the highest
average PCS shows that SAVOR-C is the safer of the two with SAVOR-D recom-
mending an unsafe dose at least 23% of the time.
For each estimator, the procedure based on least square recursion is consistently
superior to the its stochastic approximation based counterpart in both accuracy and
safety. Except for scenario 1, all virtual observation recursions have higher PCS then
the continual reassessment method. All in all, LSRVO-C seems to be the procedure
of choice given that it improves accuracy and preserves safety at the same time. The
same conclusion can be reached under a two-stage design with more aggressive initial
dose sequence and one-stage designs with starting doses at level 1 or 3 (cf. Tables
C.3, C.4, and C.5).
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Table 4.5: Operating characteristics of virtual observation recursions and the
CRM under a two stage design with n = 11, m = 3 and initial sequence
{1, 2, 3, 3, 4, 4, 4, 5, 5, 5, 5}
% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 Nν1+ NDLT
Scenario 1
P(DLT) 0.10 0.25 0.30 0.35 0.40 0.10 0.25 0.30 0.35 0.40
LSRVO 85.7 13.7 0.6 0.0 0.0 24.2 6.8 1.8 0.2 0.0 8.8 4.8
LSRVO-B 82.7 16.5 0.8 0.0 0.0 23.0 7.8 2.1 0.2 0.0 10.0 4.9
LSRVO-C 85.6 13.9 0.5 0.0 0.0 23.5 7.4 1.9 0.2 0.0 9.5 4.8
LSRVO-D 80.7 18.1 1.1 0.0 0.0 21.4 9.1 2.4 0.2 0.0 11.6 5.2
SAVOR 83.1 15.4 1.3 0.1 0.0 23.3 7.3 2.1 0.2 0.0 9.7 4.9
SAVOR-A 81.5 17.0 1.4 0.2 0.0 23.2 7.4 2.1 0.2 0.0 9.8 4.9
SAVOR-B 77.5 20.6 1.7 0.2 0.0 21.9 8.4 2.4 0.3 0.0 11.1 5.1
SAVOR-C 79.7 19.0 1.2 0.1 0.0 22.7 7.9 2.2 0.2 0.0 10.3 5.0
SAVOR-D 73.9 24.0 1.9 0.2 0.0 20.6 9.4 2.7 0.3 0.0 12.4 5.4
CRM 84.9 13.9 1.1 0.1 0.0 23.9 6.9 2.0 0.2 0.0 9.1 4.8
Scenario 2
P(DLT) 0.04 0.10 0.25 0.30 0.35 0.04 0.10 0.25 0.30 0.35
LSRVO 22.1 63.8 13.6 0.5 0.0 11.0 14.3 6.9 0.8 0.0 7.7 3.9
LSRVO-B 17.1 65.7 16.5 0.7 0.0 9.2 15.0 7.9 0.8 0.0 8.8 4.1
LSRVO-C 15.6 70.3 13.7 0.4 0.0 8.9 15.9 7.4 0.7 0.0 8.2 4.0
LSRVO-D 10.2 71.3 17.9 0.6 0.0 6.9 16.2 9.1 0.8 0.0 9.9 4.5
SAVOR 20.4 63.5 15.1 1.0 0.0 10.3 14.8 7.0 0.9 0.0 7.9 3.9
SAVOR-A 21.6 61.4 15.9 1.0 0.1 10.8 14.4 6.9 0.9 0.0 7.8 3.9
SAVOR-B 16.3 63.1 19.2 1.3 0.1 9.2 14.9 7.9 1.0 0.1 9.0 4.2
SAVOR-C 15.8 64.7 18.6 0.7 0.1 9.5 15.0 7.6 0.9 0.0 8.5 4.1
SAVOR-D 10.9 62.9 24.7 1.3 0.1 7.7 14.7 9.3 1.2 0.1 10.6 4.5
CRM 25.6 60.5 12.9 1.0 0.1 11.4 14.2 6.5 0.8 0.0 7.4 3.8
Scenario 3
P(DLT) 0.01 0.04 0.10 0.25 0.30 0.01 0.04 0.10 0.25 0.30
LSRVO 0.6 19.0 64.3 15.7 0.4 4.1 8.0 14.9 5.7 0.3 6.0 3.4
LSRVO-B 0.3 14.5 65.4 19.2 0.5 3.6 6.9 15.5 6.6 0.3 6.9 3.6
LSRVO-C 0.1 13.5 70.5 15.7 0.3 3.6 6.9 16.3 6.0 0.2 6.2 3.5
LSRVO-D 0.0 8.9 70.7 20.0 0.3 3.3 5.7 16.6 7.1 0.2 7.3 3.8
SAVOR 0.5 19.9 64.2 14.4 1.1 4.2 8.5 14.7 5.3 0.3 5.6 3.3
SAVOR-A 0.8 21.0 61.8 15.4 1.0 4.4 8.5 14.6 5.2 0.3 5.5 3.2
SAVOR-B 0.4 16.5 63.9 18.0 1.2 4.0 7.7 15.1 5.9 0.3 6.2 3.4
SAVOR-C 0.3 15.9 66.5 16.3 1.0 4.0 7.7 15.3 5.7 0.3 6.0 3.4
SAVOR-D 0.1 10.9 64.6 23.0 1.4 3.6 6.4 15.5 7.0 0.4 7.4 3.7
CRM 1.4 25.9 58.5 13.2 1.0 4.5 9.1 14.3 4.8 0.3 5.0 3.1
Scenario 4
P(DLT) 0.01 0.01 0.04 0.10 0.25 0.01 0.01 0.04 0.10 0.25
LSRVO 0.1 1.0 20.6 62.3 16.1 3.4 3.8 9.9 12.7 3.3 3.3 2.6
LSRVO-B 0.0 0.5 15.7 64.1 19.7 3.3 3.5 9.2 13.3 3.7 3.7 2.7
LSRVO-C 0.0 0.4 15.5 69.1 15.0 3.3 3.5 9.3 13.8 3.1 3.1 2.6
LSRVO-D 0.0 0.2 11.6 71.1 17.1 3.2 3.3 8.6 14.6 3.3 3.3 2.7
SAVOR 0.1 0.9 23.9 58.8 16.3 3.4 4.1 10.6 11.9 2.9 2.9 2.4
SAVOR-A 0.2 1.3 25.4 56.8 16.2 3.5 4.2 10.7 11.7 2.8 2.8 2.4
SAVOR-B 0.1 1.0 20.9 59.0 19.0 3.4 3.9 10.2 12.4 3.1 3.1 2.5
SAVOR-C 0.0 0.6 19.6 62.8 17.0 3.4 3.9 10.2 12.6 3.0 3.0 2.5
SAVOR-D 0.0 0.2 12.9 63.6 23.3 3.2 3.5 9.2 13.2 3.8 3.8 2.7
CRM 0.1 2.7 27.8 52.0 17.4 3.6 4.6 10.9 11.1 2.8 2.8 2.4
Scenario 5
P(DLT) 0.01 0.01 0.01 0.04 0.10 0.01 0.01 0.01 0.04 0.10
LSRVO 0.1 0.3 1.8 25.3 72.5 3.3 3.3 6.5 11.0 8.8 1.5
LSRVO-B 0.0 0.2 1.3 20.1 78.4 3.3 3.3 6.3 10.8 9.3 1.5
LSRVO-C 0.0 0.2 1.2 22.5 76.1 3.2 3.3 6.4 11.1 9.0 1.5
LSRVO-D 0.0 0.1 0.9 19.4 79.6 3.2 3.3 6.3 10.9 9.3 1.5
SAVOR 0.1 0.3 2.4 32.2 65.0 3.4 3.4 7.0 11.6 7.6 1.4
SAVOR-A 0.2 0.5 2.9 31.2 65.3 3.4 3.4 6.9 11.5 7.7 1.4
SAVOR-B 0.1 0.4 1.8 27.9 69.8 3.4 3.3 6.7 11.6 8.1 1.4
SAVOR-C 0.0 0.2 1.3 27.6 70.9 3.3 3.3 6.7 11.6 8.1 1.4
SAVOR-D 0.0 0.0 0.4 20.4 79.1 3.2 3.2 6.3 11.1 9.1 1.5
CRM 0.1 1.3 7.7 25.4 65.5 3.6 3.9 7.3 11.0 7.2 1.3






So far, designs using continuous outcomes require all current patients to have com-
pleted follow-up before a new cohort can be enrolled. Using the PST study as moti-
vating example, we extend least square recursion to allow continual patient accrual
through incorporating intermediate measurements.
5.2 The Procedure
We build on the setting and notations in Section 3.2. Consider a trial in which
patients are enrolled sequentially in small cohorts of size m. Each patient has two
continuous measurements taken at time points that are predetermined and identical
for all patients. The first measurement will be referred to as intermediate and the
second as final. The event of interest is said to occur if the final measurement exceeds
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threshold t0. For patient j in cohort i, the final measurement is
Yij = M(Xi) + σ(Xi)εij, (5.1)




where φ, τ > 0 and (εij, eij) has a joint distribution G with mean 0, variance 1 and
correlation ρ. In these models, φ, τ and ρ are constant across doses and we define














where Z̄i and R
2
i are the sample mean and sample variance of the intermediate mea-
surements in cohort i and Ȳi and S
2
i are those for the final measurements. In order to
keep track of follow-up status of each cohort, let nc = nc(n) be the number of cohorts
with complete follow-up prior to the entry of the first subject of cohort n + 1, and
nI = nI(n) be that with only intermediate measurements.








(Vin − t0) , (5.3)
we first define a variable that is analogous to Ui = Ȳi + cp [E (Si/σ(Xi))]
−1 Si but
based on intermediate measurements:
Win = φ̂ncZ̄i + cpτ̂nc [E (Si/σ(Xi))]
−1Ri (5.4)
for i = nc + 1, . . . , nc + nI . Next, define the virtual observation of cohort i just prior
to the entry of cohort n+ 1 as
Vin =

Vi ≡ Ui + β(X∗i −Xi) for i = 1, . . . , nc,
Win + β(X
∗
i −Xi) for i = nc + 1, . . . , nc + nI ,
t0 for i = nc + nI + 1, . . . , n.
(5.5)
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Note that we need nc ≥ 1 for φ̂n and τ̂n to exist and the proposed recursion to
work. One way to initiate the recursion is to use TITE-CRM as the initial design
until the first cohort is completely followed. With this definition of Vin patients
can be continually enrolled as they become available. Contribution of each cohort
to the proposed recursion depends on and changes with its follow-up status. Thus,
performance of the recursion hinges on patient accrual process. We first consider the
following cases:
1. Enroll the next cohort only when all current cohorts have been completely
followed.
2. Compress the enrollment process so that the intermediate outcomes from the
most recent cohort and complete outcomes from all other cohorts are available.
Under the first case, nI = 0, nc = n, Vin = Vi for all n and the propose re-
cursion reduces to LSRVO. The following result shows that under the second case,
the proposed recursion has the same consistency properties as LSRVO (recall that
G(ck) = 1− π(k) and Bk = 2σ(k)|ck − cp|):
Theorem 5.1. Let {Xn} be the design sequence generated by recursion (5.3) with
(5.5) under an accrual process such that nc(n) = n− 1 and nI(n) = 1 for all n.
(i) If Bν1 < β < mink 6=ν1 Bk then Xn = ν1 eventually with probability one
(ii) If β < mink Bk then P (Xn ∈ {ν1 − 1, ν1, ν1 + 1} eventually) = 1.
The proof of Theorem 5.1 is presented in Appendix B.2. We now turn our atten-
tion to the case where no restriction is placed on the accrual process. A simulated
trial in the context of the PST study is presented in Table 5.1 to illustrate how the
proposed recursion operates under this general case. Recall that the objective of the
study is to identify, out of five test doses, the one associated with 66% of at least
10 point improvement in quality of life (QoL) score over 8 weeks. In addition to the
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Table 5.1: Dose assignments, patients enrollment time, sample means, sample stan-
dard deviations, virtual observations and parameters estimates of a simulated trial
n 1 2 3 4 5 6 7 8 9 10
Xn 1 2 3 1 1 2 3 3 3 4
X∗n 1.00 2.00 3.00 1.00 1.00 2.00 2.50 3.03 3.16 3.54
Tn1 0.95 1.85 4.03 6.65 9.12 10.61 12.81 18.73 20.49 24.65
Tn2 1.31 2.25 4.71 6.97 9.62 12.25 15.92 18.85 24.12 26.70
Tn3 1.82 3.88 6.19 8.80 10.29 12.31 16.76 18.99 24.51 27.40
nc 0 0 0 0 1 2 5 6 6 -
nI 0 0 1 2 2 2 1 0 2 -
Z̄n 19.46 5.74 16.75 -1.96 4.19 -5.12 11.75 -5.73 -2.55 11.23
Ȳn 20.75 5.00 4.10 -1.62 15.01 -15.64 23.72 4.85 -0.97 18.07
Rn 20.96 9.26 5.88 19.00 16.47 10.63 14.10 5.60 26.96 13.46
Sn 50.51 28.78 20.00 33.95 38.93 31.45 20.16 35.86 27.35 15.69
V1n - - - - -2.76 -2.76 -2.76 -2.76 -2.76 -2.76
V2n - - - - -4.26 -8.39 -8.39 -8.39 -8.39 -8.39
V3n - - - - 11.27 10.18 -5.21 -5.21 -5.21 -5.21
V4n - - - - 10.00 -24.43 -17.43 -17.43 -17.43 -17.43
V5n - - - - 10.00 10.00 -3.11 -3.11 -3.11 -3.11
V6n - - - - - 10.00 -16.57 -30.32 -30.32 -30.32
V7n - - - - - - 10.00 10.00 -13.81 7.90
V8n - - - - - - - 10.00 -9.84 -11.41
V9n - - - - - - - - 10.00 -11.56
V10,n - - - - - - - - 4.77
φ̂nc - - - - 1.07 1.02 0.98 0.71 0.71 1.36
τ̂nc - - - - 2.41 2.54 2.33 2.39 2.39 2.04
measurement of QoL score at 8 weeks, each patient also has a planned intermediate
measurement at 4 weeks. In this example, we set X1 = 1, m = 3, n = 10, b = β = 13
and changes in QoL scores at 4 and 8 weeks are assumed to follow bivariate normal
distribution thus cp = Φ
−1(1 − 0.66) = −0.412 and [E (Si/σ(Xi))]−1 = 1.128. The
entry time of the jth patient in cohort n is denoted as Tnj in Table 5.1.
Doses for cohorts 2 to 5 are assigned by TITE-CRM as the second and third
patients in cohort 1 have not completed follow-up at the time the first patient in cohort
5 arrives. When the first patient in cohort 6 is enrolled, week 8 outcomes from cohort
1 are completely observed and dose assignment switched to the proposed recursion
with φ̂nc(5) = (20.75)/(19.46) = 1.07, τ̂nc(5) = 50.51/20.96 = 2.41, V15 = V1 = −2.76,
60
V25 = W25 = −4.26, V35 = W35 = 11.27 and V45 = V55 = t0 = 10. By the time patient










The new estimates are used to update virtual observations for cohorts 2 to 4. The
process continues until week 8 outcomes are collected from all patients. At this point,
X∗11 is calculated to be 3.59, making dose level 4 the final MED estimate.
5.3 Applications
5.3.1 Simulation Setup
Having seen how the proposed procedure operates, its operating characteristics are
examined and compared to that of TITE-CRM via simulations. Again, the context
is PST study. Four dose-response scenarios were considered (Table 5.2). Throughout
the simulations, m = 3, n = 16 and the starting dose level is 3 (6 sessions of therapy),
the prior MED. Doses were assigned by TITE-CRM before the first cohort reached
week 8 follow-up. Afterwards, the proposed procedure took over dose assignment.
Skipping an untested dose in both escalation and de-escalation was restricted by set-
ting the next assigned dose to be max{min{X∗n+1,max1≤i≤nXi+1.49},min1≤i≤nXi−
1.50}. In the current context, dose-skipping in escalation is undesirable because of
financial considerations. On the other hand, dose-skipping in de-escalation could
result in patient drop-outs due to unsatisfactory therapy results. Truncations were
applied to the estimators of φ and τ in order to restrict them to a reasonable range.
Specifically, the estimators were set to be max{min{φ̂nc , 5}, 0} and min{τ̂nc , 5}.
To generate continuous outcomes, the final 8-week outcome and intermediate 4-
week outcome were assumed to be jointly normal with mean 0 and variance 1. We
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Table 5.2: Simulation scenarios used in the PST study protocol
Dose level
Scenario 1 2 3 4 5
1 0.50 0.66 0.75 0.80 0.85
2 0.40 0.50 0.66 0.75 0.80
3 0.35 0.40 0.50 0.66 0.75
4 0.25 0.35 0.40 0.50 0.66
set σ(k), the standard deviation of 8-week outcome at dose level k, to be 32 for
all scenarios based on an internal pilot. The mean function M(k) was determined
by solving π(k) = 1 − Φ ((t0 −M(k))/σ(k)) (cf. Table C.6). Different values were
considered for the model parameters φ, τ and ρ (see details below).
5.3.2 Accrual Process
Two types of process and various rates ξ were considered for patients accrual process.
The first type of accrual process is fixed, meaning that inter-patient arrival time is
constant. Under fixed accrual process, accrual rate ξ is the number of patient(s)
enrolled in 8 weeks and 8/ξ is the fixed inter-patient arrival time. In particular, when
ξ ≤ 1, the proposed procedure reduces to LSRVO. The second and more realistic type
of accrual process assumes inter-patient arrival to follow an exponential distribution.
In this case, ξ is the average number of patient(s) enrolled in 8 weeks. We will refer
to this second type as the Poisson accrual process. Regardless of the type of process
and rate, the final MED estimate is always based on week 8 outcomes; that is, MED
is estimated after every patient has completed follow-up .
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Figure 5.1: Average PCS versus β under several patient accrual scenarios.
5.3.3 Design Calibration
The calibration process closely follows the approach in Section 4.4. Fixing b = β, β is
calibrated β under the fixed accrual process with ξ = 1. Under this particular process,
only measurements from 8 weeks were used thus the performance of the procedure
does not depend on model parameters φ, τ and ρ. The calibration steps are
1. Iterate β from 5 to 25 with a grid of 0.5.
2. Perform simulations 2000 times under each scenario and obtain PCS.
3. Choose the β that maximizes the average PCS across the 4 scenarios.
The maximum average PCS is 0.74 at β = 13. To put things into perspective,
average PCS of TITE-CRM under the same accrual process is 0.67 (see below for
specifications of the TITE-CRM). We also repeated the calibration steps under both
accrual types with several different ξ (1 to 12 with grid of 1) while setting φ = τ = 2
and ρ = 0.8. Optimal β from these accrual scenarios ranges from 12.5 to 13.5 with
maximum average PCS oscillating between 0.74 and 0.75. These results suggest that
13 is indeed a reasonable choice of β. The average PCS against β from some of the
accrual scenarios are plotted in Figure 5.1.
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5.3.4 Specifications of TITE-CRM
The empiric function was used as dose response model. Specifically, for dose k with
label dk, the probability of response was assumed to be d
exp(a)
k , where a is a priori
normal with mean 0 and variance 1.34. The following weight function was adopted:
w(t) =

0 if t < 4
0.5 if 4 ≤ t < 8
1 if t ≥ 8.
Restrictions on dose skipping in escalation and de-escalation were enforced. Cali-
bration of initial guesses of response probability followed the approach of Lee and
Cheung [18].
5.3.5 Results
We first investigate the impact of accrual process on the performance of the proposed
procedure. In this set of simulation, the model parameters are fixed at φ = 2, τ = 2
and ρ = 0.8 and ξ ranges from 1 to 12 with grid of 1. Operating characteristics of
the proposed procedure and TITE-CRM are plotted in Figure 5.2 and tabulated in
Tables C.7 and C.8. While results from both accrual processes are presented in the
figure and tables, the discussion below focuses on the fixed process as results from
the two processes lead to similar conclusions.
In terms of accuracy, PCS from both the proposed procedure and TITE-CRM
exhibit similar patterns in that it increases slightly with ξ under the first three sce-
narios, and drops more markedly under scenario 4. In particular, for the proposed
procedure, PCS at ξ = 1, 3, 6, 9, 12 are 0.67, 0.68, 0.68, 0.70 , 0.69 under scenario
1; 0.69, 0.71, 0.70, 0.73, 0.73 under scenario 2 and 0.72, 0.73, 0.73, 0.73, 0.73 under
scenario 3 and 0.89, 0.86, 0.86, 0.83, 0.82 under scenario 4.
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Figure 5.2: Operating characteristics of the proposed procedure (left panel) and TITE-
CRM (right panel) against accrual rate ξ. Solid lines indicate fixed accrual process. Dashed
lines indicate Poisson accrual process. The numbers on the lines denote scenario.
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Figure 5.3: Average accrual duration against accrual rate ξ.
While percentage of correct selection suggests that compressing accrual process
does not seem to take its toll on accuracy, the adverse impact of fast accrual can be
seen in the increase number of patients treated below MED. Between the two designs,
TITE-CRM seems to be more susceptible to this negative impact under scenarios 1
and 2. The numbers increase from 7.9 at ξ = 1 to 16.4 at ξ = 12 under scenario 1 and
from 10.8 to 18.1 under scenario 2 for TITE-CRM. In comparison, the increase is more
modest for the proposed procedure: from 5.7 to 8.0 under scenario 1 and from 8.2 to
13.9 under scenario 2. The increases under scenarios 3 and 4 are more pronounced
but comparable for both designs. In particular, the numbers increase from 11.7 at
ξ = 1 to 21.1 at ξ = 12 under scenario 3; from 15.3 to 26.0 under scenario 4 for
the proposed procedure. Another undesirable feature due to compressed accrual is
decreased number of responses. However, the decreases are slight with a worst drop
of 2.7 responses from ξ = 1 to 12 under scenario 4 for both designs.
When compared to the TITE-CRM, the proposed procedure is uniformly supe-
rior in that it identifies the correct MED more often, selects an ineffective dose less
frequently, treats fewer patients at ineffective doses and results in higher number or
responses. Although its performance deteriorates as ξ increases, the drop in perfor-
mance is moderate when compared to the considerably shortened trial duration as ξ
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gets larger (Figure 5.3).
So far, we have looked at the operating characteristics of the proposed procedure
under one particular set of model parameters. To evaluate the impact of these pa-
rameters on the procedure’s performance, we ran simulations with different values of
φ, τ and ρ. While different ξ were considered, only results with ξ = 6 are shown
(Figure 5.4) as similar conclusions can be reached with other values of ξ. The top
panel of Figure 5.4 shows PCS and number of patients treated below MED of the
procedure with ξ = 6, τ = 2, ρ = 0.8 and φ ranges from 0.1 to 4. As can be seen,
except for very slight drops under scenario 4 when φ is small and under scenarios 1
to 3 when φ is extreme, the procedure’s performance does not seem to depend on
true value of φ. In contrast, when φ is fixed at 2 and τ allowed to vary (second panel
of Figure 5.4), the drop in performance with small τ under scenarios 1 to 3 becomes
more pronounced. This is because a small τ/φ ratio corresponds to large variation
in the week 4 outcomes and as a result, less accurate φ estimates due to truncation.
When τ/φ is fixed to be 1, the patterns are similar to those in the first panel. Finally,
results when ρ ranges from 0.05 to 0.95 and both φ and τ are fixed at 2 show that
ρ does not affect the performance of the procedure (bottom panel). These results
show that the procedure is fairly consistent under a wide range and combination of
model parameters even when the tuning parameters are chosen irrespective of these
parameters.
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φ = 2,  τ = 2
Figure 5.4: Operating characteristics of the proposed recursion with b = β = 13,
ξ = 6 and various combinations of φ, τ and ρ. Solid line: fixed accrual process.




This dissertation considers dose finding studies where a binary outcome is obtained
by dichotomizing a continuous measurement and has two major contributions. The
first contribution is that we improved the performance of virtual observation recur-
sions through pooling data in variance estimation. In accordance with the conclusion
reached in Section 3.5 that parametric assumption on variance should be avoided,
σ(x) is left unspecified in model (3.1) and only nonparametric methods were consid-
ered. Asymptotic and simulation results show that least square recursion can benefit
substantially from the proposed estimators, especially when an extreme quantile is
targeted. In particular, σ̄kn strikes the best balance between accuracy and safety. In
contrast, asymptotic performance of stochastic approximation seems to be burdened
by the use of more data. Empirically, the proposed estimators tend to be too ag-
gressive and offer only marginal improvement in accuracy. The second contribution
of this dissertation is in extending least square recursion to incorporate intermediate
outcomes. This is accomplished by taking advantage of least square recursion’s abil-
ity to work with a triangle array of virtual observations Vin. Theoretical results of
the proposed procedure under a simplified accrual scenario is provided. Results on
more general accrual process need to be developed. Also, the estimator σ̄kn can be
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incorporated to improve performance.
It is natural to ask the question whether the idea of pooling data across cohorts

























Just like using σ̌kn makes no difference, using Ỹkn provides no advantage for LSR-
based procedures. Arguments analogous to those in the proof of Proposition 4.1 can
show that recursion (3.16) with (6.1) is equivalent to LSRVO. On the other hand,
(3.10) with (6.2) generates different design sequence from that of SAVOR. Preliminary
simulation results show that using (6.2) worsens the performance of recursion (3.10).
Another important comment is that in order to implement virtual observation
recursion, it is necessary to specify β and b. Instead of calibrating both parameters in
a two dimensional space, we choose b based on asymptotic consideration and restrict
attention to calibrating β in both Chapters 4 and 5. In particular, in Section 4.4, the
upper bound 0.83 used in the calibration of β depends on π(k) and σ(k), quantities
that are typically unknown. To address this issue, we note that with both Conditions
3.5 and 3.6 satisfied, a upper bound for β can be obtained from (3.13). Letting
pL = 0.04 and pU = 0.25, then this new upper bound is 0.63 under all scenario using
true σ(ν). An estimate of the upper bound can be obtained by approximating σ(ν)
by 0.59, the 80% lower confidence limit based on the 20 observations in the combined
dose levels 3 and 4 from NeuSTART. The resulting estimated upper bound, 0.41,
while conservative, still allows a wide enough range for calibration.
Throughout the dissertation, we consider the case when the binary outcome is
obtained by dichotomizing a single continuous measurement. It is common however,
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that a binary outcome is defined on several continuous measurements. It would be of
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A.1 Conditions for Stochastic Approximation
Condition A.1. Q(x∗) = α and (x− x∗)(Q(x)− α) > 0 for all x 6= x∗
Condition A.2. For all x and some positive constants D1 and D2,
D1|x− x∗| ≤ |Q(x)− α| ≤ D2|x− x∗|
Condition A.3. (a) supx VarY (x) <∞ (b) limx→x∗ VarY (x) exists.
Condition A.4. Q(x) = α + α1(x − x∗) + δ(x, x∗) where δ(x, x∗) = o(|x − x∗|) as
x→ x∗ and α1 > 0.
Condition A.5. For some ε1 > 0 and some ε2 > 0, sup|x−x∗|<ε1 E|Y (x)|
2+ε2 <∞.
A.2 Conditions for SAVOR
The following condition on h(x) is extracted from Cheung and Elkind [9].
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Condition A.6. One and only one of the following statements is true:
1. The equation h(x) = t0 has a unique root, denoted by θb, not among the jump
points {l2, . . . , lK}.
2. The root of h(x) = t0 does not exist.
3. The equation h(x) = t0 has multiple roots, with the smallest root denoted by θ
′






























Proof of Lemma 4.1 for LSR-based procedures. We first prove the results for LSRVO-



















(Vi,n−1 − t0) .
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(σ̃kn − σ̃k,n−1) 1{Xi = k}
= Ȳn + cp
K∑
k=1




nk,n−1 (σ̃kn − σ̃k,n−1)
= h(X∗n) + σ(xn)(ε̄n − cp) + cp
K∑
k=1
(nknσ̃kn − nk,n−1σ̃k,n−1) .
(B.2)
Next, expanding σ̃kn around σ(k) gives



















for some τ̃kn between σ(k) and σ̃kn.
Substituting nknσ̃kn − nk,n−1σ̃k,n−1































































n1{Xn = k}, (B.5)

















(nknη̃kn − nk,n−1η̃k,n−1) .
It is easy to verify that
∑∞
n=1E(en | Fn−1) = 0 a.s. We next show that
∑∞
n=1E(|ξn| |







(S2n − σ2(k))1{Xn = k} (B.6)
Given δ > 0, n
1/2−δ
kn D̃kn → 0 on {nkn →∞} (B.7)
Property (B.7) can be obtained by applying Corollary 5 of Chow (1965) [11] (with






i − σ2(k)) 1{Xi =
k},Fn, n ≥ 1}. Note that (B.7) implies
σ̃2kn → σ2(k) on {nkn →∞}. (B.8)
Now, from (B.3) and (B.6),
























































Fixing 0 < δ < 1/2, then from (B.7) we have
∑∞























1{Xn = k} <∞ a.s.
This finishes the proof for LSRVO-B.









































for some τ̂kn between σ(k) and σ̂kn. To derive an expression for nknσ̂
2
kn−nk,n−1σ̂2k,n−1,






























l=1 1{Xl = k}
∑m
j=1(εlj − ε̄l)2 +m
∑n








l=1 1{Xl = k}ε̄2l
nkn
− σ2(k)ε̃2kn. (B.10)








































































































−2ε̄nε̃k,n−1 + ε̃2k,n−1 − n−1kn (ε̄n − ε̃k,n−1)
2] 1{Xn = k}.
Again, it is easy to verify E(en | Fn−1) = 0 a.s. The next step is to show
∑∞
n=1E(|ξn| |
Fn−1) < ∞ a.s. First, for any δ > 0, applications of Colrollary 5 of [11] and Kro-
























→ 0 on {nkn →∞}, (B.12)
n
1/2−δ





























1{Xn = k} <∞ a.s.,






|ε̃2k,n−1 − n−1kn (ε̄n − ε̃k,n−1)
2 | | Fn−1
)
1{Xn =




k=1E (|nknη̂kn − nk,n−1η̂k,n−1| | Fn−1) <














and for any δ > 0, as a consequence of (B.10), (B.7), (B.12) and (B.13),
n
1/2−δ
















→ 0 on {nkn →∞}. (B.14)
Now,




















































The desired result follows from applying the same arguments from the proof of
LSRVO-B.










































for some τ̄kn between σ(k) and σ̄kn.
For an expression of nknη̄kn − nk,n−1η̄k,n−1 we rely on the relationship between σ̄2kn







































− 1{Xn = k}
mnkn − 1
σ̄2k,n−1.
































































1{Xn = k} <∞ a.s. (B.18)
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Let D̄kn = σ̄
2








and due to (B.14), for any δ > 0,
n
1/2−δ








→ 0 on {nkn →∞}. (B.19)
The above result implies σ̄2kn → σ2(k) on {nkn →∞} which immediately establishes
(B.17). Observing that



























































(B.18) can be verified by following the same approach as before. This completes the
proof of Lemma 4.1 for LSR-based procedures.
Proof of Lemma 4.1 for SA-based procedures. We prove the results for SAVOR-B. Re-
sults for SAVOR-C and SAVOR-D can be obtained analogously. The design sequence
















h(X∗n) + σ(Xn)ε̄n + cp
K∑
k=1

















where η̃kn is defined in (B.3).
































































(∣∣∣∣η̃kn − σ̃2kn − σ2(k)2σ(k)
∣∣∣∣ 1{Xn = k} | Fn−1) <∞ a.s.
This shows that SAVOR-B can be represented by the general form (4.5).















(σ̌kn − σ(k)) 1{Xn = k}.





−1 Sn − σ(k)
}
1{Xn =








|σ̌k,n−1 − σ(k)|1{Xn = k} <∞ a.s..








−1 Si − σ(k)
}
1{Xi = k},Fn, n ≥ 1
}
for some
0 < δ < 1/2.
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Proof of Theorem 4.1 (i). Under the conditions, h(x) = t0 has a unique root at θβ.
Moreover, C(θβ) = ν1. Thus it remains to show that X
∗
n will converge to θβ with
probability one.






(h(X∗n) + en − t0) + ξn,
where E(en | Fn−1) = 0 and
∑∞
n=1E(|ξn| | Fn−1) < ∞ almost surely. Repeatedly
applying the inequalities (a1 + a2)
2 ≤ 2a21 + 2a22 and 2a1a2 ≤ a21 + a22 gives,
(X∗n+1 − θβ)2 ≤(X∗n − θβ)2 −
2
nb




(h(X∗n) + en − t0)2 + 2ξ2n
≤(X∗n − θβ)2(1 + |ξn|)−
2
nb





















where the last inequality follows since |h(X∗n)| = |f(Xn) + β(X∗n −Xn)| = |f(Xn) +
β(X∗n − θβ) + β(θβ −Xn)| ≤ |β(X∗n − θβ)|+O(1).
Taking conditional expectation with respect to Fn−1 gives
E
(








(X∗n − θβ) (h(X∗n)− t0)




+ 2ξ2n | Fn−1
)
+O(n−2).










< ∞ a.s. Hence, Theorem 1
of Robbins and Siegmund (1971) [26] implies that limn→∞(X
∗
n+1 − θβ)2 exists and∑∞
n=1 n
−1(X∗n − θβ) (h(X∗n)− t0) < ∞ a.s. Since (X∗n − θβ) (h(X∗n)− t0) > 0 for
X∗n 6= θβ, we have X∗n → θβ and Xn = C(θβ) = ν1 eventually almost surely.
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Proof of Theorem 4.1 (ii). When π(ν1) < p, h(ν1 + 0.5−) < t0 and h(ν1 + 0.5) > t0.
Replacing θβ with ν1 + 0.5 in the proof of (i) gives X
∗
n → ν1 + 0.5 a.s. Similarly, we
can show X∗n → ν1 − 0.5 a.s. when π(ν1) > p.
Proof of Theorem 4.2 (i). For LSR-based procedures, we prove the result for LSRVO-
C. Results for LSRVO-B and LSRVO-D can be established in similar but simpler
arguments.









if 0 ≤ i < n








From equation 2.3, Lemmas 2, 5 and 3 of Sacks [27], we have the following properties
(a) (1− δi) iρn−ρ ≤ γin ≤ (1 + δi) iρn−ρ where δi → 0 as i→∞ (B.20a)
(b) lim
n→∞
wnγin = 0 for fixed i (B.20b)
(c) wn ∼ ρ−1(2ρ− 1)1/2n1/2 = (b(2β − b))1/2 β−1n1/2 (B.20c)






ρ2j−2γ2jnWj = W, for fixed j0. (B.20d)






(h(X∗n) + en − t0) + ξn













and ξn is defined in (B.16).
Since h(X∗n) = f(Xn) + β(X
∗
n −Xn) and t0 = h(θβ) = f(ν1) + β(θβ − ν1),
X∗n+1 − θβ = (X∗n − θβ)−
1
nb













(f(Xn)− f(ν1)− β(Xn − ν1)) + ξn.
Iterating the above yields








































A direct application of (B.20b) gives (B.21a). As for (B.21c), we use (B.20a), (B.20c)








iρ−1 (f(Xi)− f(ν1)− β(Xi − ν1))→ 0 a.s.
Next, we verify (B.21b). Let Qin = wnb
−1i−1γinei, then Qin ∈ Fi and E (Qin | Fi−1) =
0 a.s. By evoking the martingale central limit theorem in [23] (p. 171), it suffices to









(1 + κ) , (B.22a)
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(1 + κ) a.s.
by (B.20d).
We now verify (B.22b). Fix δ > 0, then using (B.20a) and (B.20c),
|Qin| > δ =⇒ |ei| > w−1n b i|γ−1in | δ





=⇒ |ei| > δ′ i1/2,
































Since δ is arbitrary this completes the proof of (B.21b).












































To show that the above will converge to 0 in probability, we tackle each term in
turns. To handle the first term we follow the algebraic steps in the proof of Kronecker’s




k=1 (nklη̄kl − nk,l−1η̄k,l−1)
=
∑K
k=1 nkiη̄ki = O(n
δ
ki), then n































iρ−1 − (i− 1)ρ−1
)
ci−1
When ρ > 1, n1/2−ρ
∑n
i=1 (i



























Next, fix 0 < δ < min{1/4, ρ−1/2}, then
{∑n
i=1 i
−1/2+δ ε̄iε̃k,i−11{Xi = k},Fn, n ≥ 1
}
















ε̄iε̃k,i−11{Xi = k} → 0 a.s.
The rest of the terms in (B.23) can be shown to converge to 0 a.s. by similar argu-
ments. This completes the proof of Theorem 4.2 (i).
Proof of Theorem 4.2 (ii). We prove the result for SAVOR-C. Results for SAVOR-


















1{Xn = k} − t0
}
.
Using the facts h(X∗n)− t0 = β(X∗n− θβ) + f(Xn)− f(ν1) +β(Xn− ν1), ρ = β/b gives
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1 − θβ) → 0 a.s. and wn
∑n
i=1 γinRi → 0 a.s. can be obtained by
using arguments from previous proofs.






































































+ ε̄2i − 1
)]
1{Xi = ν1}, then E (Qin | Fi−1) =



















Q2in1{|Qin| > δ} | Fi−1
) P−→ 0 for every δ > 0. (B.25b)
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−→ 0 + 2ρ−3 − 0
















The limits of the first two terms follow from (B.20d) and the limit of last term can


































j−2γjn (γjn − γ0n) −→ ρ−3 − 0.
This completes the verification of (B.25a).
























































































































Before giving the proof of Theorem 5.1, we first derive some preparatory results

























































































































j=1 (eij − ēi)
2 − 1
]
all converge to 0 a.s. Thus, φ̂n → φ a.s. and τ̂ 2n → τ 2 a.s.
Proof of Theorem 5.1. It suffices to prove (i). Let Fn−1 be the σ-field generated by
{X∗i , εi1, . . . , εim, ei1, . . . , eim}, i = 1, . . . , n−1, and D1, D2, . . . are positive constants
appropriately chosen according to the context.



















(Vi,n−1 − t0) .











(Vin − Vi,n−1) . (B.26)
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where ∆i = Ui −Wii.
Rearranging the above and repeatedly applying the inequalities (a1 +a2)
2 ≤ 2a21 +2a22
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n + (Xn − θβ)2 + t20
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The last equality uses
Vn = Un + β(X
∗










− (Xn − θβ)
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.











































which in turns implies 1
n−1∆n−1 → 0 a.s. as n → ∞, then by Theorem 1 of
Robbins and Siegmund, limn→∞
(








−1 (X∗n − θβ) (h(X∗n)− t0) < ∞ a.s. Together with the fact that
(X∗n − θβ) (h(X∗n)− t0) > 0, we would have X∗n → θβ a.s.
It remains to verify (B.27). First, since supnM(Xn) <∞ and supn σ(Xn) <∞,
U2n−1 =
(



















j=1 (εn−1,j − ε̄n−1)














































Table C.1: Asymptotic variances of the virtual observation recursions under standard
normal noises









































































Table C.2: Dose-limiting toxicity probability, mean function and standard deviation
function of the continuous outcomes used in Section 4.4
Dose level
Scenario 1 2 3 4 5
1 P(DLT) 0.10 0.25 0.30 0.35 0.40
M(k) 3.63 4.16 4.30 4.44 4.56
σ(k) 0.92 0.96 0.97 0.98 0.99
2 P(DLT) 0.04 0.10 0.25 0.30 0.35
M(k) 3.26 3.63 4.16 4.30 4.44
σ(k) 0.89 0.92 0.96 0.97 0.98
3 P(DLT) 0.01 0.04 0.10 0.25 0.30
M(k) 2.86 3.26 3.63 4.16 4.30
σ(k) 0.84 0.89 0.92 0.96 0.97
4 P(DLT) 0.01 0.01 0.04 0.10 0.25
M(k) 2.86 2.86 3.26 3.63 4.16
σ(k) 0.84 0.84 0.89 0.92 0.96
5 P(DLT) 0.01 0.01 0.01 0.04 0.10
M(k) 2.86 2.86 2.86 3.26 3.63
σ(k) 0.84 0.84 0.84 0.89 0.92
100
Table C.3: Operating characteristics of virtual observation recursions and the
CRM under a two stage design with n = 11, m = 3 and initial sequence
{1, 2, 3, 4, 5, 5, 5, 5, 5, 5, 5}
% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 Nν1+ NDLT
Scenario 1
P(DLT) 0.10 0.25 0.30 0.35 0.40 0.10 0.25 0.30 0.35 0.40
LSRVO 85.4 13.9 0.7 0.0 0.0 24.1 6.8 1.6 0.4 0.1 8.9 4.8
LSRVO-B 82.0 16.8 1.1 0.1 0.0 22.8 7.8 1.9 0.4 0.1 10.2 5.0
LSRVO-C 84.7 14.6 0.6 0.1 0.0 23.3 7.4 1.8 0.4 0.1 9.7 4.9
LSRVO-D 79.5 18.4 2.0 0.1 0.0 21.2 9.0 2.3 0.4 0.1 11.8 5.3
SAVOR 81.9 15.8 2.0 0.3 0.0 23.3 6.9 2.0 0.6 0.2 9.7 5.0
SAVOR-A 79.6 17.6 2.4 0.3 0.1 22.9 7.3 2.1 0.6 0.2 10.1 5.0
SAVOR-B 75.9 20.8 2.9 0.4 0.1 21.7 8.1 2.4 0.7 0.2 11.3 5.2
SAVOR-C 78.0 19.2 2.4 0.4 0.0 22.2 7.8 2.2 0.6 0.2 10.8 5.1
SAVOR-D 71.5 24.9 3.1 0.5 0.0 20.2 9.3 2.7 0.7 0.2 12.8 5.5
CRM 84.1 14.4 1.4 0.1 0.0 23.9 6.9 1.8 0.4 0.1 9.1 4.9
Scenario 2
P(DLT) 0.04 0.10 0.25 0.30 0.35 0.04 0.10 0.25 0.30 0.35
LSRVO 21.9 62.4 14.9 0.8 0.0 11.0 13.9 6.4 1.3 0.4 8.1 4.0
LSRVO-B 16.6 64.8 17.8 0.9 0.0 9.0 14.8 7.4 1.4 0.4 9.2 4.3
LSRVO-C 15.3 69.0 15.1 0.6 0.0 8.8 15.4 7.0 1.4 0.4 8.8 4.2
LSRVO-D 9.8 68.2 20.7 1.3 0.0 6.8 15.4 8.6 1.8 0.4 10.8 4.7
SAVOR 20.7 59.1 17.7 2.4 0.1 10.6 13.4 6.5 1.9 0.6 9.0 4.2
SAVOR-A 20.6 58.8 17.9 2.5 0.2 10.5 13.6 6.4 1.9 0.6 8.9 4.2
SAVOR-B 15.7 59.5 21.4 3.1 0.3 9.1 13.9 7.3 2.1 0.6 10.1 4.5
SAVOR-C 14.5 61.9 20.7 2.7 0.2 8.9 14.4 7.1 2.0 0.6 9.7 4.4
SAVOR-D 9.8 59.8 26.5 3.6 0.3 7.4 13.9 8.7 2.4 0.7 11.7 4.8
CRM 25.2 59.7 13.8 1.2 0.1 11.3 14.0 5.9 1.3 0.5 7.7 3.9
Scenario 3
P(DLT) 0.01 0.04 0.10 0.25 0.30 0.01 0.04 0.10 0.25 0.30
LSRVO 0.6 19.2 63.0 16.4 0.8 4.1 8.1 13.2 6.0 1.6 7.6 3.7
LSRVO-B 0.3 14.6 64.9 19.3 0.9 3.6 7.0 13.8 6.9 1.6 8.5 3.9
LSRVO-C 0.1 13.6 69.1 16.6 0.6 3.6 6.9 14.4 6.6 1.6 8.1 3.9
LSRVO-D 0.0 8.5 68.2 22.4 0.9 3.3 5.6 14.2 8.2 1.7 9.9 4.3
SAVOR 0.4 18.4 60.3 19.8 1.1 4.3 7.9 12.4 6.5 2.0 8.4 3.8
SAVOR-A 0.7 19.6 58.6 19.2 1.9 4.4 8.2 12.2 6.2 2.0 8.2 3.8
SAVOR-B 0.4 14.9 59.2 23.2 2.2 4.0 7.2 12.5 7.1 2.2 9.3 4.0
SAVOR-C 0.3 14.1 61.5 22.3 1.8 3.9 7.2 12.8 6.9 2.1 9.0 4.0
SAVOR-D 0.1 9.1 59.6 28.9 2.3 3.6 6.0 12.8 8.3 2.4 10.7 4.4
CRM 1.4 26.2 57.9 13.5 1.0 4.5 9.5 12.4 4.9 1.7 6.5 3.4
Scenario 4
P(DLT) 0.01 0.01 0.04 0.10 0.25 0.01 0.01 0.04 0.10 0.25
LSRVO 0.1 1.1 21.5 62.6 14.7 3.4 3.9 7.9 11.7 6.1 6.1 3.1
LSRVO-B 0.0 0.5 16.7 66.7 16.1 3.3 3.6 7.0 12.7 6.5 6.5 3.3
LSRVO-C 0.0 0.4 16.0 70.0 13.6 3.3 3.5 7.0 13.0 6.2 6.2 3.2
LSRVO-D 0.0 0.2 10.5 72.0 17.4 3.2 3.3 5.8 13.6 7.1 7.1 3.4
SAVOR 0.1 0.8 19.3 64.8 15.0 3.5 3.9 7.2 12.0 6.4 6.4 3.2
SAVOR-A 0.2 1.3 20.8 61.0 16.7 3.5 4.0 7.5 11.6 6.4 6.4 3.1
SAVOR-B 0.1 0.8 16.0 63.4 19.7 3.4 3.8 6.8 11.9 7.1 7.1 3.3
SAVOR-C 0.0 0.6 14.8 66.7 17.9 3.4 3.7 6.8 12.1 7.0 7.0 3.3
SAVOR-D 0.0 0.1 9.5 65.8 24.5 3.2 3.4 5.8 12.4 8.2 8.2 3.6
CRM 0.1 2.7 31.5 55.0 10.7 3.6 4.7 9.2 10.1 5.4 5.4 2.8
Scenario 5
P(DLT) 0.01 0.01 0.01 0.04 0.10 0.01 0.01 0.01 0.04 0.10
LSRVO 0.1 0.2 1.9 24.9 72.8 3.3 3.3 4.0 7.5 14.9 1.9
LSRVO-B 0.0 0.2 1.4 22.0 76.3 3.3 3.3 3.7 7.3 15.5 1.9
LSRVO-C 0.0 0.2 1.2 21.2 77.5 3.2 3.3 3.7 7.2 15.5 2.0
LSRVO-D 0.0 0.1 0.8 16.7 82.4 3.2 3.2 3.5 6.5 16.6 2.0
SAVOR 0.1 0.3 1.4 26.8 71.4 3.4 3.3 3.9 7.6 14.8 1.9
SAVOR-A 0.2 0.5 2.3 25.0 72.0 3.4 3.4 4.0 7.3 14.9 1.9
SAVOR-B 0.1 0.4 1.4 21.2 76.9 3.4 3.3 3.7 6.8 15.8 1.9
SAVOR-C 0.0 0.3 1.2 20.7 77.8 3.3 3.3 3.7 6.9 15.8 2.0
SAVOR-D 0.0 0.0 0.3 14.4 85.3 3.2 3.2 3.4 6.2 17.1 2.0
CRM 0.1 1.3 7.8 27.3 63.5 3.6 3.9 4.8 7.3 13.4 1.8
Nν1+: number treated above ν1; NDLT: total number of DLT
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Table C.4: Operating characteristics of virtual observation recursions and the CRM
under a one stage design with X1 = 1, n = 11 and m = 3
% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 Nν1+ NDLT
Scenario 1
P(DLT) 0.10 0.25 0.30 0.35 0.40 0.10 0.25 0.30 0.35 0.40
LSRVO 85.9 13.5 0.6 0.0 0.0 25.3 6.5 1.0 0.1 0.0 7.7 4.5
LSRVO-B 83.4 15.9 0.7 0.0 0.0 24.2 7.4 1.3 0.1 0.0 8.8 4.7
LSRVO-C 86.2 13.3 0.5 0.0 0.0 24.7 7.1 1.2 0.1 0.0 8.3 4.6
LSRVO-D 82.8 16.2 0.9 0.0 0.0 22.7 8.7 1.6 0.1 0.0 10.3 5.0
SAVOR 87.0 12.6 0.4 0.0 0.0 26.0 6.1 0.8 0.1 0.0 7.0 4.4
SAVOR-A 84.0 15.3 0.6 0.1 0.0 25.4 6.6 0.9 0.1 0.0 7.6 4.5
SAVOR-B 80.5 18.5 0.9 0.0 0.0 23.9 7.8 1.2 0.1 0.0 9.1 4.8
SAVOR-C 82.5 16.6 0.9 0.0 0.0 24.3 7.6 1.0 0.1 0.0 8.7 4.7
SAVOR-D 74.0 24.1 1.8 0.1 0.0 21.3 9.9 1.7 0.1 0.0 11.7 5.2
CRM 84.1 14.4 1.4 0.1 0.0 23.9 6.9 1.8 0.4 0.1 9.1 4.9
Scenario 2
P(DLT) 0.04 0.10 0.25 0.30 0.35 0.04 0.10 0.25 0.30 0.35
LSRVO 21.3 63.2 14.8 0.6 0.0 11.6 14.5 6.0 0.8 0.0 6.9 3.7
LSRVO-B 16.9 65.8 16.6 0.7 0.0 9.8 15.4 6.9 0.9 0.0 7.9 4.0
LSRVO-C 15.4 69.8 14.2 0.6 0.0 9.5 16.0 6.6 0.8 0.0 7.5 3.9
LSRVO-D 10.5 71.7 17.2 0.6 0.0 7.5 16.6 7.9 0.9 0.0 8.9 4.3
SAVOR 24.7 61.5 13.5 0.3 0.0 12.9 14.4 5.2 0.5 0.0 5.7 3.4
SAVOR-A 23.6 61.9 13.9 0.5 0.0 12.8 14.5 5.1 0.5 0.0 5.7 3.4
SAVOR-B 17.8 64.0 17.5 0.7 0.0 10.6 15.5 6.3 0.7 0.0 7.0 3.8
SAVOR-C 15.7 67.9 16.0 0.4 0.0 10.1 16.3 6.1 0.5 0.0 6.6 3.7
SAVOR-D 9.0 66.2 23.8 1.0 0.0 7.3 16.3 8.4 0.9 0.0 9.4 4.3
CRM 25.2 59.7 13.8 1.2 0.1 11.3 14.0 5.9 1.3 0.5 7.7 3.9
Scenario 3
P(DLT) 0.01 0.04 0.10 0.25 0.30 0.01 0.04 0.10 0.25 0.30
LSRVO 0.5 18.4 64.0 16.2 0.8 4.5 8.2 13.8 5.9 0.7 6.5 3.4
LSRVO-B 0.3 14.5 65.8 18.6 0.8 4.0 7.3 14.4 6.6 0.7 7.3 3.7
LSRVO-C 0.1 13.2 70.2 15.9 0.6 3.9 7.1 15.0 6.3 0.6 7.0 3.6
LSRVO-D 0.0 9.4 71.8 18.2 0.5 3.5 6.2 15.6 7.2 0.5 7.8 3.8
SAVOR 0.9 22.9 63.1 12.9 0.2 5.2 9.8 13.6 4.2 0.2 4.4 2.9
SAVOR-A 1.1 24.8 59.7 14.0 0.4 5.4 10.2 13.0 4.1 0.3 4.4 2.9
SAVOR-B 0.5 19.2 62.4 17.3 0.6 4.5 9.0 14.1 5.0 0.3 5.3 3.2
SAVOR-C 0.3 17.6 67.1 14.7 0.3 4.3 8.9 14.8 4.7 0.3 5.0 3.2
SAVOR-D 0.1 10.1 67.0 22.3 0.5 3.6 6.9 15.4 6.7 0.4 7.1 3.7
CRM 1.4 26.2 57.9 13.5 1.0 4.5 9.5 12.4 4.9 1.7 6.5 3.4
Scenario 4
P(DLT) 0.01 0.01 0.04 0.10 0.25 0.01 0.01 0.04 0.10 0.25
LSRVO 0.1 1.0 20.5 63.2 15.2 4.0 4.0 8.0 12.2 4.8 4.8 2.8
LSRVO-B 0.0 0.7 17.1 65.9 16.4 3.7 3.7 7.4 13.0 5.2 5.2 3.0
LSRVO-C 0.0 0.4 15.7 69.5 14.4 3.6 3.7 7.3 13.5 4.9 4.9 3.0
LSRVO-D 0.0 0.3 13.3 72.7 13.7 3.4 3.5 6.8 14.5 4.7 4.7 3.0
SAVOR 0.1 1.4 25.6 61.3 11.6 4.1 4.6 9.7 11.8 2.8 2.8 2.4
SAVOR-A 0.2 2.1 28.4 57.5 11.8 4.3 5.0 9.9 10.9 2.9 2.9 2.3
SAVOR-B 0.1 1.1 22.3 61.7 14.8 3.8 4.3 9.1 12.2 3.6 3.6 2.6
SAVOR-C 0.0 0.7 21.1 65.7 12.5 3.8 4.2 9.1 12.7 3.1 3.1 2.5
SAVOR-D 0.0 0.3 12.8 67.9 19.0 3.3 3.6 7.3 14.0 4.7 4.7 3.0
CRM 0.1 2.7 31.5 55.0 10.7 3.6 4.7 9.2 10.1 5.4 5.4 2.8
Scenario 5
P(DLT) 0.01 0.01 0.01 0.04 0.10 0.01 0.01 0.01 0.04 0.10
LSRVO 0.1 0.4 2.5 25.4 71.6 4.0 3.7 4.3 8.2 12.8 1.7
LSRVO-B 0.0 0.3 2.0 23.5 74.1 3.7 3.5 4.1 8.1 13.6 1.8
LSRVO-C 0.0 0.2 1.7 22.6 75.6 3.6 3.5 4.1 8.1 13.7 1.8
LSRVO-D 0.0 0.2 1.6 22.4 75.8 3.4 3.4 3.9 8.4 13.8 1.8
SAVOR 0.1 0.3 2.5 31.2 65.9 4.1 3.9 4.9 9.5 10.6 1.6
SAVOR-A 0.2 1.0 4.2 31.9 62.6 4.2 4.3 5.1 9.2 10.2 1.5
SAVOR-B 0.1 0.5 2.9 26.9 69.5 3.8 3.9 4.6 8.9 11.8 1.7
SAVOR-C 0.0 0.4 2.3 27.5 69.8 3.7 3.9 4.6 9.2 11.6 1.6
SAVOR-D 0.0 0.1 0.9 18.1 80.9 3.3 3.5 3.9 8.1 14.2 1.9
CRM 0.1 1.3 7.8 27.3 63.5 3.6 3.9 4.8 7.3 13.4 1.8
Nν1+: number treated above ν1; NDLT: total number of DLT
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Table C.5: Operating characteristics of virtual observation recursions and the CRM
under a one stage design with X1 = 3, n = 11 and m = 3
% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 Nν1+ NDLT
Scenario 1
P(DLT) 0.10 0.25 0.30 0.35 0.40 0.10 0.25 0.30 0.35 0.40
LSRVO 81.4 17.1 1.4 0.1 0.0 20.6 6.5 5.1 0.8 0.1 12.4 5.5
LSRVO-B 76.5 21.0 2.3 0.2 0.0 18.2 8.0 5.7 1.0 0.1 14.8 5.9
LSRVO-C 80.7 17.8 1.4 0.1 0.0 19.2 7.4 5.4 0.9 0.1 13.8 5.8
LSRVO-D 72.8 24.2 2.7 0.2 0.0 15.7 9.3 6.4 1.4 0.2 17.3 6.4
SAVOR 81.7 17.0 1.2 0.1 0.0 20.7 6.5 5.0 0.7 0.0 12.3 5.5
SAVOR-A 80.3 17.8 1.7 0.2 0.0 20.6 6.5 4.9 0.9 0.1 12.4 5.5
SAVOR-B 74.6 22.5 2.5 0.4 0.0 18.4 7.7 5.6 1.1 0.1 14.6 5.9
SAVOR-C 76.0 21.1 2.7 0.2 0.0 18.4 7.8 5.6 1.0 0.1 14.6 5.9
SAVOR-D 61.1 32.9 5.3 0.7 0.0 13.9 10.2 7.1 1.6 0.2 19.1 6.7
CRM 77.6 19.7 2.6 0.2 0.0 18.4 7.7 5.1 1.4 0.4 14.6 6.0
Scenario 2
P(DLT) 0.04 0.10 0.25 0.30 0.35 0.04 0.10 0.25 0.30 0.35
LSRVO 21.5 64.8 13.2 0.6 0.0 9.3 13.8 8.4 1.4 0.1 9.9 4.4
LSRVO-B 15.6 67.9 15.8 0.7 0.0 6.8 14.7 9.6 1.8 0.2 11.5 4.8
LSRVO-C 15.4 71.1 12.9 0.6 0.0 7.1 14.8 9.2 1.7 0.2 11.1 4.7
LSRVO-D 10.0 70.9 18.0 1.0 0.1 4.4 14.9 10.8 2.5 0.4 13.7 5.3
SAVOR 21.5 65.3 12.7 0.5 0.0 9.3 13.9 8.4 1.4 0.1 9.8 4.3
SAVOR-A 23.0 60.3 15.7 1.0 0.0 9.7 12.5 8.8 1.8 0.2 10.8 4.5
SAVOR-B 16.1 62.3 20.0 1.5 0.0 7.3 13.0 10.2 2.3 0.3 12.7 4.9
SAVOR-C 13.7 66.8 18.2 1.2 0.1 6.8 13.8 10.1 2.0 0.2 12.4 4.9
SAVOR-D 6.8 63.3 27.2 2.5 0.2 3.7 13.2 12.5 3.0 0.4 16.0 5.7
CRM 20.3 63.3 15.2 1.2 0.0 7.4 14.7 8.0 2.2 0.6 10.8 4.7
Scenario 3
P(DLT) 0.01 0.04 0.10 0.25 0.30 0.01 0.04 0.10 0.25 0.30
LSRVO 0.6 20.0 66.1 12.8 0.5 1.7 6.9 17.2 6.4 0.8 7.2 3.9
LSRVO-B 0.3 15.2 68.5 15.5 0.6 0.9 5.5 18.0 7.5 1.1 8.5 4.2
LSRVO-C 0.1 14.0 72.9 12.5 0.4 1.0 5.3 18.5 7.2 1.1 8.3 4.2
LSRVO-D 0.0 9.7 72.6 16.9 0.9 0.4 3.6 18.2 8.9 1.8 10.7 4.8
SAVOR 0.6 20.4 67.0 11.7 0.4 1.7 7.1 17.6 6.1 0.6 6.7 3.8
SAVOR-A 1.2 21.3 62.4 14.4 0.7 2.5 6.8 16.3 6.6 0.9 7.5 3.8
SAVOR-B 0.5 15.2 65.4 18.0 0.9 1.5 5.3 17.0 8.0 1.3 9.2 4.3
SAVOR-C 0.2 13.1 69.9 15.9 0.8 1.2 5.0 18.0 7.7 1.0 8.7 4.3
SAVOR-D 0.1 6.6 67.2 24.5 1.6 0.5 3.0 17.5 10.3 1.8 12.0 5.0
CRM 0.8 23.2 63.3 12.2 0.5 1.1 8.1 16.2 6.1 1.7 7.7 4.0
Scenario 4
P(DLT) 0.01 0.01 0.04 0.10 0.25 0.01 0.01 0.04 0.10 0.25
LSRVO 0.1 1.0 20.3 66.6 12.0 0.5 1.4 9.9 15.5 5.6 5.6 3.4
LSRVO-B 0.0 0.5 16.1 69.3 14.1 0.3 0.9 8.7 16.3 6.8 6.8 3.7
LSRVO-C 0.0 0.2 14.9 72.5 12.4 0.3 0.9 8.3 16.8 6.7 6.7 3.7
LSRVO-D 0.0 0.0 10.3 72.6 17.0 0.1 0.4 6.7 16.6 9.2 9.2 4.3
SAVOR 0.1 1.1 21.5 67.1 10.2 0.5 1.5 10.5 15.9 4.5 4.5 3.2
SAVOR-A 0.2 1.5 22.7 62.3 13.2 0.9 1.7 10.3 14.7 5.4 5.4 3.2
SAVOR-B 0.0 0.6 17.3 65.2 16.9 0.5 1.1 8.9 15.6 6.9 6.9 3.7
SAVOR-C 0.0 0.4 15.7 69.1 14.9 0.4 1.0 8.7 16.5 6.4 6.4 3.6
SAVOR-D 0.0 0.1 8.8 68.4 22.8 0.1 0.4 6.7 16.7 9.1 9.1 4.2
CRM 0.1 1.5 28.4 61.5 8.5 0.1 1.9 11.0 14.4 5.5 5.5 3.3
Scenario 5
P(DLT) 0.01 0.01 0.01 0.04 0.10 0.01 0.01 0.01 0.04 0.10
LSRVO 0.0 0.1 1.1 19.7 79.1 0.1 0.4 4.4 8.8 19.2 2.3
LSRVO-B 0.0 0.0 0.6 15.8 83.6 0.1 0.2 3.9 7.9 20.9 2.4
LSRVO-C 0.0 0.0 0.3 13.6 86.0 0.1 0.2 3.8 7.4 21.5 2.5
LSRVO-D 0.0 0.0 0.1 9.0 90.9 0.0 0.1 3.4 5.9 23.7 2.6
SAVOR 0.0 0.2 1.2 24.2 74.5 0.1 0.4 4.7 10.6 17.1 2.2
SAVOR-A 0.1 0.2 1.9 25.4 72.4 0.3 0.6 4.9 10.1 17.0 2.2
SAVOR-B 0.0 0.0 0.9 19.6 79.4 0.1 0.3 4.3 9.0 19.3 2.3
SAVOR-C 0.0 0.1 0.6 18.2 81.1 0.1 0.3 4.1 9.0 19.5 2.3
SAVOR-D 0.0 0.0 0.2 10.6 89.2 0.0 0.1 3.5 7.0 22.4 2.6
CRM 0.0 0.1 2.6 32.1 65.2 0.0 0.4 4.9 10.5 17.1 2.2
Nν1+: number treated above ν1; NDLT: total number of DLT
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Table C.6: Probability of response and mean function of the continuous outcomes
used in Section 5.3
Dose level
Scenario 1 2 3 4 5
1 P(Rsp) 0.50 0.66 0.75 0.80 0.85
M(k) 10.00 23.20 31.58 36.93 43.17
2 P(Rsp) 0.40 0.50 0.66 0.75 0.80
M(k) 1.89 10.00 23.20 31.58 36.93
3 P(Rsp) 0.35 0.40 0.50 0.66 0.75
M(k) -2.33 1.89 10.00 23.20 31.58
4 P(Rsp) 0.25 0.35 0.40 0.50 0.66
M(k) -11.58 -2.33 1.89 10.00 23.20
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Table C.7: Operating characteristics of (5.3) with (5.5) (b = β = 13, φ = τ = 2, ρ = 0.8)
% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 NMED- NRsp
Scenario 1
P(Rsp) 0.50 0.66 0.75 0.80 0.85 0.50 0.66 0.75 0.80 0.85
Fixed, ξ = 1 6.6 66.6 25.1 1.8 0.0 5.7 23.1 15.5 3.4 0.3 5.7 32.6
Fixed, ξ = 2 6.5 65.8 26.1 1.7 0.0 6.0 22.6 15.5 3.4 0.5 6.0 32.6
Fixed, ξ = 3 6.6 67.5 24.5 1.4 0.0 6.0 23.7 15.5 2.5 0.2 6.0 32.5
Fixed, ξ = 4 6.8 68.3 23.5 1.4 0.0 6.1 24.6 14.7 2.4 0.2 6.1 32.4
Fixed, ξ = 5 6.2 66.8 25.3 1.6 0.0 6.8 22.5 14.8 3.6 0.4 6.8 32.4
Fixed, ξ = 6 6.3 67.5 24.8 1.4 0.0 6.9 22.9 14.6 3.3 0.3 6.9 32.3
Fixed, ξ = 7 6.2 67.4 25.3 1.0 0.0 5.0 22.5 18.4 2.0 0.1 5.0 32.7
Fixed, ξ = 8 6.2 68.4 24.6 0.8 0.0 6.2 22.2 17.6 1.8 0.2 6.2 32.4
Fixed, ξ = 9 6.4 69.8 23.1 0.8 0.0 7.0 23.1 16.1 1.7 0.1 7.0 32.2
Fixed, ξ = 10 6.4 70.5 22.4 0.6 0.0 7.4 23.3 15.8 1.4 0.1 7.4 32.0
Fixed, ξ = 11 6.0 68.7 24.9 0.4 0.0 7.6 21.8 16.0 2.4 0.2 7.6 32.2
Fixed, ξ = 12 6.0 69.0 24.5 0.4 0.0 8.0 21.8 15.8 2.2 0.2 8.0 32.1
Poisson, ξ = 1 6.6 66.0 25.9 1.5 0.0 5.8 22.8 15.8 3.2 0.3 5.8 32.6
Poisson, ξ = 2 6.4 66.8 25.2 1.5 0.0 6.0 23.0 15.7 3.1 0.3 6.0 32.6
Poisson, ξ = 3 6.6 66.5 25.4 1.4 0.0 6.0 22.9 15.8 3.0 0.3 6.0 32.6
Poisson, ξ = 4 6.4 67.1 25.1 1.4 0.0 6.1 22.6 16.2 2.9 0.3 6.1 32.5
Poisson, ξ = 5 6.3 67.0 25.6 1.1 0.0 6.0 22.6 16.5 2.6 0.3 6.0 32.5
Poisson, ξ = 6 6.5 67.6 24.9 0.9 0.0 6.2 22.5 16.6 2.5 0.3 6.2 32.5
Poisson, ξ = 7 6.4 68.0 24.6 0.8 0.0 6.3 22.3 16.9 2.3 0.2 6.3 32.4
Poisson, ξ = 8 6.2 68.4 24.6 0.8 0.0 6.4 22.2 17.0 2.2 0.2 6.4 32.4
Poisson, ξ = 9 5.9 68.7 24.6 0.7 0.0 6.6 22.2 17.1 2.0 0.2 6.6 32.4
Poisson, ξ = 10 6.2 68.8 24.4 0.6 0.0 6.8 22.0 17.2 1.8 0.2 6.8 32.3
Poisson, ξ = 11 6.1 69.0 24.3 0.5 0.0 7.0 21.9 17.3 1.7 0.1 7.0 32.3
Poisson, ξ = 12 6.2 69.0 24.6 0.3 0.0 7.2 21.5 17.5 1.6 0.1 7.2 32.2
Scenario 2
P(Rsp) 0.40 0.50 0.66 0.75 0.80 0.40 0.50 0.66 0.75 0.80
Fixed, ξ = 1 0.0 8.5 69.2 21.5 0.8 0.7 7.5 26.5 11.6 1.7 8.2 31.5
Fixed, ξ = 2 0.0 8.4 68.7 22.2 0.7 0.8 8.0 25.6 11.6 2.0 8.8 31.5
Fixed, ξ = 3 0.0 8.4 71.2 19.7 0.6 0.9 9.4 26.1 10.4 1.2 10.3 31.0
Fixed, ξ = 4 0.0 8.4 71.3 19.7 0.6 0.9 9.8 25.5 10.5 1.3 10.7 31.0
Fixed, ξ = 5 0.0 8.5 69.9 21.1 0.5 1.6 9.4 23.9 11.4 1.7 11.0 31.0
Fixed, ξ = 6 0.0 8.6 70.4 20.4 0.5 1.6 9.7 24.2 11.1 1.4 11.3 30.9
Fixed, ξ = 7 0.0 8.5 72.1 19.1 0.4 0.6 8.5 28.5 9.4 1.0 9.1 31.1
Fixed, ξ = 8 0.0 8.7 72.2 18.8 0.3 1.5 9.3 27.6 8.7 1.0 10.8 30.7
Fixed, ξ = 9 0.0 9.4 73.0 17.4 0.2 2.2 11.0 26.2 8.0 0.6 13.2 30.1
Fixed, ξ = 10 0.0 9.5 73.8 16.5 0.2 2.5 11.2 26.3 7.4 0.6 13.7 29.9
Fixed, ξ = 11 0.0 9.3 73.0 17.5 0.1 2.7 10.8 25.1 8.6 0.9 13.5 30.1
Fixed, ξ = 12 0.0 9.4 73.1 17.3 0.1 3.0 10.9 25.1 8.1 0.9 13.9 29.9
Poisson, ξ = 1 0.0 8.3 70.0 21.0 0.6 0.9 8.1 26.1 11.4 1.6 9.0 31.4
Poisson, ξ = 2 0.0 8.3 70.3 20.8 0.5 1.0 8.5 25.9 11.1 1.5 9.5 31.2
Poisson, ξ = 3 0.0 8.5 71.1 20.1 0.4 1.1 8.8 25.9 10.8 1.4 9.9 31.1
Poisson, ξ = 4 0.0 8.5 71.1 20.0 0.4 1.2 9.0 25.8 10.7 1.3 10.2 31.0
Poisson, ξ = 5 0.0 8.7 71.2 19.7 0.4 1.3 9.3 25.9 10.3 1.2 10.6 30.9
Poisson, ξ = 6 0.0 8.8 71.9 18.9 0.4 1.4 9.6 26.0 9.9 1.1 11.0 30.8
Poisson, ξ = 7 0.0 9.1 72.2 18.2 0.4 1.6 9.7 26.5 9.3 1.0 11.2 30.6
Poisson, ξ = 8 0.0 9.2 72.5 17.9 0.3 1.8 10.0 26.5 8.8 0.9 11.7 30.5
Poisson, ξ = 9 0.0 9.0 73.2 17.4 0.4 2.0 10.3 26.7 8.2 0.9 12.2 30.3
Poisson, ξ = 10 0.0 9.1 73.6 17.1 0.2 2.3 10.4 26.7 7.9 0.8 12.6 30.1
Poisson, ξ = 11 0.0 9.1 73.9 16.9 0.2 2.5 10.6 26.6 7.6 0.8 13.0 30.1
Poisson, ξ = 12 0.0 9.5 73.6 16.8 0.1 2.7 10.8 26.6 7.2 0.7 13.5 29.9
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% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 NMED- NRsp
Scenario 3
P(Rsp) 0.35 0.40 0.50 0.66 0.75 0.35 0.40 0.50 0.66 0.75
Fixed, ξ = 1 0.0 0.1 9.0 71.8 19.1 0.1 1.2 10.3 25.5 10.8 11.7 30.6
Fixed, ξ = 2 0.0 0.1 9.0 71.6 19.2 0.2 1.8 10.5 24.4 11.1 12.5 30.4
Fixed, ξ = 3 0.0 0.1 9.9 72.6 17.4 0.2 3.0 11.7 23.7 9.5 14.9 29.8
Fixed, ξ = 4 0.0 0.1 9.8 73.1 17.1 0.2 3.3 11.4 23.8 9.3 14.9 29.7
Fixed, ξ = 5 0.0 0.1 10.1 72.2 17.6 0.5 3.0 11.2 23.5 9.8 14.7 29.8
Fixed, ξ = 6 0.0 0.1 10.4 72.5 17.0 0.5 3.3 11.6 23.5 9.2 15.4 29.6
Fixed, ξ = 7 0.0 0.0 9.0 73.3 17.6 0.1 1.9 14.5 22.6 8.9 16.5 29.6
Fixed, ξ = 8 0.0 0.0 9.9 73.0 17.1 0.4 2.6 15.4 20.8 8.8 18.4 29.2
Fixed, ξ = 9 0.0 0.2 11.3 73.4 15.2 0.8 4.1 15.4 20.9 6.9 20.3 28.5
Fixed, ξ = 10 0.0 0.2 11.6 73.6 14.6 0.9 4.4 15.9 20.2 6.6 21.2 28.2
Fixed, ξ = 11 0.0 0.0 11.3 73.3 15.3 0.9 4.0 15.5 20.0 7.5 20.5 28.5
Fixed, ξ = 12 0.0 0.0 11.5 73.0 15.6 1.1 4.2 15.8 19.5 7.4 21.1 28.3
Poisson, ξ = 1 0.0 0.1 9.2 71.8 19.0 0.2 1.9 10.9 24.6 10.5 12.9 30.3
Poisson, ξ = 2 0.0 0.1 9.3 72.2 18.2 0.2 2.2 11.2 24.2 10.1 13.7 30.1
Poisson, ξ = 3 0.0 0.1 9.6 73.0 17.3 0.2 2.5 11.8 23.7 9.7 14.5 29.9
Poisson, ξ = 4 0.0 0.0 10.0 72.5 17.4 0.3 2.7 12.4 23.2 9.4 15.4 29.7
Poisson, ξ = 5 0.0 0.1 10.2 72.5 17.3 0.4 2.9 12.9 22.8 9.1 16.1 29.5
Poisson, ξ = 6 0.0 0.1 10.6 72.4 16.9 0.4 3.1 13.7 22.1 8.8 17.2 29.3
Poisson, ξ = 7 0.0 0.1 10.7 72.7 16.5 0.5 3.3 14.1 21.7 8.3 17.9 29.1
Poisson, ξ = 8 0.0 0.0 11.0 72.6 16.4 0.5 3.5 14.8 21.2 8.0 18.8 28.9
Poisson, ξ = 9 0.0 0.0 10.8 73.4 15.8 0.6 3.6 15.6 20.7 7.5 19.8 28.7
Poisson, ξ = 10 0.0 0.0 11.1 73.5 15.4 0.7 3.9 16.2 20.0 7.2 20.8 28.4
Poisson, ξ = 11 0.0 0.0 11.2 73.2 15.5 0.8 4.1 16.7 19.6 6.8 21.6 28.2
Poisson, ξ = 12 0.0 0.1 11.4 73.6 14.9 0.9 4.3 17.6 18.6 6.6 22.7 28.0
Scenario 4
P(Rsp) 0.25 0.35 0.40 0.50 0.66 0.25 0.35 0.40 0.50 0.66
Fixed, ξ = 1 0.0 0.0 0.3 10.8 88.9 0.0 0.4 4.5 10.3 32.7 15.3 28.6
Fixed, ξ = 2 0.0 0.0 0.2 11.6 88.1 0.0 0.8 4.7 10.7 31.8 16.2 28.4
Fixed, ξ = 3 0.0 0.0 0.4 14.1 85.5 0.1 1.8 6.0 11.8 28.4 19.6 27.6
Fixed, ξ = 4 0.0 0.0 0.3 14.3 85.4 0.1 2.1 5.6 12.0 28.4 19.6 27.6
Fixed, ξ = 5 0.0 0.0 0.4 13.6 86.1 0.2 1.7 5.3 12.5 28.3 19.7 27.6
Fixed, ξ = 6 0.0 0.0 0.3 14.1 85.6 0.2 1.9 5.6 12.7 27.6 20.4 27.5
Fixed, ξ = 7 0.0 0.0 0.2 13.6 86.2 0.0 0.8 8.9 11.5 26.8 21.2 27.2
Fixed, ξ = 8 0.0 0.0 0.3 14.7 85.0 0.1 1.3 9.9 11.7 25.1 22.9 26.7
Fixed, ξ = 9 0.0 0.0 0.3 17.1 82.7 0.4 2.6 9.3 13.6 22.1 25.9 26.0
Fixed, ξ = 10 0.0 0.0 0.4 17.5 82.2 0.4 2.8 10.0 13.3 21.5 26.5 25.8
Fixed, ξ = 11 0.0 0.0 0.4 17.1 82.5 0.4 2.3 9.9 13.1 22.3 25.7 26.0
Fixed, ξ = 12 0.0 0.0 0.4 17.3 82.2 0.5 2.5 10.0 13.1 22.0 26.0 25.9
Poisson, ξ = 1 0.0 0.0 0.3 12.0 87.6 0.1 0.9 5.1 10.9 31.0 17.0 28.2
Poisson, ξ = 2 0.0 0.0 0.3 12.6 87.1 0.1 1.2 5.5 11.3 29.9 18.1 28.0
Poisson, ξ = 3 0.0 0.0 0.2 13.0 86.8 0.1 1.4 6.0 11.8 28.7 19.3 27.7
Poisson, ξ = 4 0.0 0.0 0.4 13.8 85.8 0.1 1.5 6.6 12.0 27.9 20.1 27.5
Poisson, ξ = 5 0.0 0.0 0.4 14.0 85.7 0.1 1.6 7.2 12.1 26.9 21.1 27.3
Poisson, ξ = 6 0.0 0.0 0.3 14.8 85.0 0.2 1.7 7.9 12.4 25.8 22.2 26.9
Poisson, ξ = 7 0.0 0.0 0.4 14.9 84.7 0.2 1.8 8.6 12.6 24.7 23.3 26.7
Poisson, ξ = 8 0.0 0.0 0.3 15.5 84.2 0.3 1.9 9.4 12.8 23.7 24.3 26.4
Poisson, ξ = 9 0.0 0.0 0.3 16.2 83.5 0.3 2.1 9.9 13.1 22.6 25.4 26.1
Poisson, ξ = 10 0.0 0.0 0.2 17.2 82.6 0.3 2.2 10.7 13.1 21.6 26.4 25.8
Poisson, ξ = 11 0.0 0.0 0.2 17.8 82.0 0.3 2.4 11.4 13.3 20.6 27.4 25.6
Poisson, ξ = 12 0.0 0.0 0.4 18.2 81.5 0.4 2.5 12.1 13.2 19.7 28.3 25.3
P(Rsp): probability or response; NMED-: number treated below MED; NRsp: total number of responses
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Table C.8: Operating characteristics of TITE-CRM
% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 NMED- NRsp
Scenario 1
P(Rsp) 0.50 0.66 0.75 0.80 0.85 0.50 0.66 0.75 0.80 0.85
Fixed, ξ = 1 11.7 59.5 25.8 2.9 0.1 7.9 20.4 16.0 3.4 0.3 7.9 32.3
Fixed, ξ = 2 11.4 60.8 24.9 2.9 0.0 8.6 21.1 14.8 3.2 0.3 8.6 32.0
Fixed, ξ = 3 12.2 59.1 25.9 2.6 0.0 8.9 22.0 14.1 2.7 0.3 8.9 31.9
Fixed, ξ = 4 11.6 61.1 24.9 2.2 0.0 9.7 22.5 13.3 2.4 0.2 9.7 31.6
Fixed, ξ = 5 11.8 60.1 25.9 2.1 0.0 10.1 21.0 13.4 3.2 0.2 10.1 31.7
Fixed, ξ = 6 11.5 61.4 25.5 1.6 0.0 10.8 21.4 12.7 2.9 0.2 10.8 31.4
Fixed, ξ = 7 11.2 63.3 23.8 1.7 0.0 9.9 20.3 16.2 1.6 0.1 9.9 31.6
Fixed, ξ = 8 10.9 63.7 23.9 1.4 0.0 10.7 20.3 15.6 1.3 0.1 10.7 31.4
Fixed, ξ = 9 11.9 62.7 23.8 1.6 0.0 11.9 20.2 14.2 1.7 0.1 11.9 31.2
Fixed, ξ = 10 11.6 62.7 24.1 1.6 0.0 13.0 20.0 13.6 1.3 0.1 13.0 30.9
Fixed, ξ = 11 10.9 63.2 24.4 1.4 0.0 12.5 19.3 14.0 2.1 0.1 12.5 31.1
Fixed, ξ = 12 11.0 63.6 24.1 1.3 0.0 13.4 19.3 13.2 2.0 0.1 13.4 30.9
Poisson, ξ = 1 11.6 59.9 25.7 2.7 0.0 8.4 21.2 15.2 2.9 0.3 8.4 32.1
Poisson, ξ = 2 11.5 61.0 25.4 2.1 0.0 9.0 21.3 14.7 2.8 0.3 9.0 31.9
Poisson, ξ = 3 11.8 60.4 25.6 2.2 0.0 9.3 21.2 14.6 2.7 0.2 9.3 31.8
Poisson, ξ = 4 12.1 60.8 24.8 2.3 0.0 9.7 21.1 14.5 2.4 0.2 9.7 31.7
Poisson, ξ = 5 11.2 61.2 25.5 2.1 0.0 10.1 20.9 14.5 2.2 0.2 10.1 31.6
Poisson, ξ = 6 11.8 61.2 25.4 1.6 0.0 10.5 20.6 14.6 2.1 0.2 10.5 31.5
Poisson, ξ = 7 11.2 62.4 25.1 1.2 0.0 10.8 20.3 14.9 2.0 0.1 10.8 31.5
Poisson, ξ = 8 11.5 62.7 24.6 1.2 0.0 11.5 19.9 14.7 1.8 0.1 11.5 31.3
Poisson, ξ = 9 11.5 63.8 23.2 1.5 0.0 11.9 19.6 14.8 1.7 0.1 11.9 31.3
Poisson, ξ = 10 10.8 63.6 24.2 1.3 0.0 12.3 19.1 15.0 1.5 0.1 12.3 31.2
Poisson, ξ = 11 11.2 62.5 25.1 1.2 0.0 12.7 18.7 15.1 1.4 0.1 12.7 31.1
Poisson, ξ = 12 11.3 63.2 24.1 1.4 0.0 13.0 18.5 15.1 1.4 0.1 13.0 31.1
Scenario 2
P(Rsp) 0.40 0.50 0.66 0.75 0.80 0.40 0.50 0.66 0.75 0.80
Fixed, ξ = 1 0.2 13.4 62.6 22.3 1.5 1.6 9.2 24.9 10.6 1.8 10.8 31.0
Fixed, ξ = 2 0.2 12.6 63.6 22.1 1.4 1.7 10.0 24.8 10.0 1.5 11.6 30.7
Fixed, ξ = 3 0.2 13.3 63.4 21.6 1.5 1.9 11.1 23.8 9.7 1.5 13.0 30.5
Fixed, ξ = 4 0.1 12.8 64.6 21.0 1.4 2.5 11.6 23.6 9.1 1.3 14.0 30.2
Fixed, ξ = 5 0.1 14.1 63.3 21.2 1.1 2.8 11.4 22.7 9.8 1.3 14.2 30.2
Fixed, ξ = 6 0.1 13.9 65.0 19.9 1.1 3.1 12.1 22.5 9.2 1.1 15.2 29.9
Fixed, ξ = 7 0.1 13.2 64.8 21.1 0.8 2.6 11.2 25.7 7.7 0.8 13.8 29.9
Fixed, ξ = 8 0.0 13.3 65.4 20.4 0.8 3.0 11.7 25.4 7.2 0.6 14.8 29.7
Fixed, ξ = 9 0.1 13.2 65.7 20.5 0.5 4.0 12.6 23.4 7.3 0.7 16.6 29.3
Fixed, ξ = 10 0.0 13.8 66.1 19.5 0.6 4.7 13.1 23.1 6.4 0.7 17.8 29.0
Fixed, ξ = 11 0.1 13.6 65.6 20.0 0.8 4.4 12.7 22.7 7.4 0.7 17.1 29.2
Fixed, ξ = 12 0.1 14.2 65.0 20.1 0.7 5.0 13.1 22.5 6.8 0.7 18.1 28.9
Poisson, ξ = 1 0.2 13.4 63.6 21.3 1.4 1.8 10.0 24.6 10.1 1.6 11.7 30.8
Poisson, ξ = 2 0.1 13.4 63.5 21.6 1.4 2.0 10.5 24.1 9.9 1.5 12.6 30.5
Poisson, ξ = 3 0.1 13.9 63.7 20.8 1.5 2.3 10.9 23.9 9.5 1.4 13.2 30.4
Poisson, ξ = 4 0.1 13.8 63.3 21.6 1.1 2.6 11.3 23.7 9.1 1.3 13.9 30.1
Poisson, ξ = 5 0.1 13.0 64.4 21.5 1.0 2.8 11.7 23.7 8.6 1.2 14.5 30.0
Poisson, ξ = 6 0.2 13.8 64.5 20.5 1.0 3.0 12.0 23.7 8.3 1.0 15.0 29.8
Poisson, ξ = 7 0.1 13.8 65.5 19.9 0.8 3.3 12.1 23.8 7.9 0.8 15.4 29.7
Poisson, ξ = 8 0.1 13.8 64.7 20.5 0.9 3.6 12.2 23.7 7.7 0.8 15.8 29.5
Poisson, ξ = 9 0.1 14.1 64.1 21.0 0.7 3.8 12.6 23.6 7.3 0.7 16.4 29.3
Poisson, ξ = 10 0.1 13.6 65.2 20.4 0.6 4.2 12.7 23.6 6.8 0.6 16.9 29.2
Poisson, ξ = 11 0.0 13.6 65.8 20.1 0.6 4.6 12.7 23.4 6.7 0.6 17.3 29.0
Poisson, ξ = 12 0.1 14.2 64.8 20.3 0.5 4.9 12.8 23.6 6.1 0.5 17.7 28.9
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% Recommendation # Treated
1 2 3 4 5 1 2 3 4 5 NMED- NRsp
Scenario 3
P(Rsp) 0.35 0.40 0.50 0.66 0.75 0.35 0.40 0.50 0.66 0.75
Fixed, ξ = 1 0.0 0.4 13.6 64.7 21.2 0.3 1.7 13.4 22.8 9.8 15.4 29.8
Fixed, ξ = 2 0.0 0.4 14.1 65.2 20.3 0.4 2.6 13.0 23.0 9.0 16.0 29.6
Fixed, ξ = 3 0.0 0.4 15.8 63.5 20.2 0.5 3.8 13.2 21.6 8.9 17.5 29.2
Fixed, ξ = 4 0.0 0.4 15.7 64.4 19.5 0.7 4.2 13.7 21.4 8.0 18.6 28.9
Fixed, ξ = 5 0.0 0.5 15.6 64.1 19.9 0.8 3.9 13.7 21.6 8.0 18.3 28.9
Fixed, ξ = 6 0.0 0.4 15.8 65.0 18.7 0.9 4.5 14.1 21.4 7.0 19.5 28.6
Fixed, ξ = 7 0.0 0.4 13.2 66.8 19.7 0.5 3.2 17.4 19.8 7.1 21.2 28.5
Fixed, ξ = 8 0.0 0.4 14.1 66.3 19.3 0.7 3.6 17.7 19.3 6.7 22.0 28.2
Fixed, ξ = 9 0.0 0.4 15.5 65.9 18.2 1.2 5.0 16.7 18.9 6.2 22.9 27.8
Fixed, ξ = 10 0.0 0.6 15.3 66.5 17.5 1.6 5.5 17.4 18.0 5.6 24.4 27.4
Fixed, ξ = 11 0.0 0.4 15.4 66.5 17.7 1.2 5.1 17.5 18.3 5.9 23.8 27.6
Fixed, ξ = 12 0.0 0.4 15.8 66.6 17.1 1.5 5.4 17.9 17.7 5.5 24.8 27.4
Poisson, ξ = 1 0.0 0.4 14.2 65.6 19.8 0.4 2.6 13.3 22.7 9.0 16.2 29.5
Poisson, ξ = 2 0.0 0.5 14.1 65.5 19.9 0.5 3.1 13.7 22.1 8.6 17.3 29.3
Poisson, ξ = 3 0.0 0.5 14.8 64.5 20.2 0.6 3.5 14.1 21.6 8.3 18.2 29.0
Poisson, ξ = 4 0.0 0.5 15.2 65.0 19.4 0.7 3.7 14.6 21.3 7.7 18.9 28.8
Poisson, ξ = 5 0.0 0.2 14.7 65.1 19.9 0.7 3.9 15.2 20.8 7.4 19.8 28.6
Poisson, ξ = 6 0.0 0.4 14.5 66.1 19.0 0.8 4.1 15.9 20.2 7.1 20.8 28.4
Poisson, ξ = 7 0.0 0.5 14.2 66.1 19.1 0.9 4.3 16.4 19.6 6.8 21.6 28.2
Poisson, ξ = 8 0.0 0.4 14.5 66.5 18.6 1.0 4.6 17.2 18.8 6.4 22.8 27.9
Poisson, ξ = 9 0.0 0.4 15.1 66.4 18.1 1.1 4.8 17.7 18.3 6.1 23.6 27.7
Poisson, ξ = 10 0.0 0.5 14.7 66.8 18.0 1.2 5.1 18.3 17.6 5.9 24.6 27.5
Poisson, ξ = 11 0.0 0.4 14.9 67.6 17.1 1.3 5.3 18.7 17.3 5.5 25.3 27.3
Poisson, ξ = 12 0.0 0.5 15.8 66.7 17.0 1.4 5.5 19.4 16.5 5.3 26.2 27.1
Scenario 4
P(Rsp) 0.25 0.35 0.40 0.50 0.66 0.25 0.35 0.40 0.50 0.66
Fixed, ξ = 1 0.0 0.0 0.4 16.9 82.7 0.1 0.6 5.9 12.8 28.5 19.5 27.8
Fixed, ξ = 2 0.0 0.0 0.5 17.6 81.8 0.1 1.0 5.9 13.4 27.6 20.4 27.6
Fixed, ξ = 3 0.0 0.0 0.8 19.9 79.4 0.2 2.1 6.4 13.7 25.7 22.3 27.0
Fixed, ξ = 4 0.0 0.0 0.5 19.8 79.7 0.3 2.3 6.7 14.1 24.7 23.3 26.8
Fixed, ξ = 5 0.0 0.0 0.6 20.0 79.5 0.3 2.0 6.5 14.7 24.5 23.5 26.8
Fixed, ξ = 6 0.0 0.0 0.8 19.4 79.9 0.3 2.3 7.0 15.1 23.2 24.8 26.5
Fixed, ξ = 7 0.0 0.0 0.6 18.9 80.5 0.2 1.3 10.8 13.5 22.2 25.8 26.1
Fixed, ξ = 8 0.0 0.0 0.8 19.1 80.1 0.2 1.6 11.2 13.9 21.1 26.9 25.9
Fixed, ξ = 9 0.0 0.0 0.8 21.9 77.3 0.5 2.9 10.1 14.9 19.7 28.3 25.5
Fixed, ξ = 10 0.0 0.0 0.9 22.9 76.2 0.6 3.3 11.0 14.8 18.3 29.7 25.1
Fixed, ξ = 11 0.0 0.0 0.8 22.4 76.8 0.5 2.6 11.2 14.8 18.9 29.1 25.3
Fixed, ξ = 12 0.0 0.0 0.9 23.5 75.5 0.6 2.9 11.6 14.9 18.1 29.9 25.1
Poisson, ξ = 1 0.0 0.0 0.6 17.8 81.5 0.1 1.1 6.3 13.1 27.4 20.6 27.5
Poisson, ξ = 2 0.0 0.0 0.6 18.6 80.8 0.2 1.5 6.7 13.7 26.0 22.0 27.2
Poisson, ξ = 3 0.0 0.0 0.6 18.8 80.6 0.2 1.7 7.1 13.9 25.1 22.9 26.9
Poisson, ξ = 4 0.0 0.0 0.8 19.1 80.2 0.3 1.8 7.8 14.2 24.0 24.0 26.6
Poisson, ξ = 5 0.0 0.0 0.8 19.7 79.5 0.2 2.0 8.4 14.2 23.0 25.0 26.4
Poisson, ξ = 6 0.0 0.0 0.8 20.0 79.2 0.3 2.1 9.1 14.5 22.0 26.0 26.1
Poisson, ξ = 7 0.0 0.0 0.9 20.5 78.6 0.3 2.3 9.8 14.5 21.1 26.9 25.9
Poisson, ξ = 8 0.0 0.0 0.8 20.5 78.8 0.4 2.3 10.6 14.7 20.1 27.9 25.6
Poisson, ξ = 9 0.0 0.0 0.8 22.0 77.2 0.4 2.5 11.3 14.5 19.2 28.8 25.4
Poisson, ξ = 10 0.0 0.0 0.7 21.9 77.3 0.4 2.6 12.0 14.6 18.3 29.7 25.1
Poisson, ξ = 11 0.0 0.0 0.9 22.7 76.4 0.5 2.8 12.6 14.8 17.4 30.6 24.9
Poisson, ξ = 12 0.0 0.0 0.9 22.6 76.5 0.5 2.9 13.3 14.6 16.7 31.3 24.7
P(Rsp): probability or response; NMED-: number treated below MED; NRsp: total number of responses
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